<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Redox Biol</journal-id><journal-id journal-id-type="iso-abbrev">Redox Biol</journal-id><journal-title-group><journal-title>Redox Biology</journal-title></journal-title-group><issn pub-type="epub">2213-2317</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40324316</article-id><article-id pub-id-type="pmc">PMC12099462</article-id><article-id pub-id-type="pii">S2213-2317(25)00174-0</article-id><article-id pub-id-type="doi">10.1016/j.redox.2025.103661</article-id><article-id pub-id-type="publisher-id">103661</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Oxidative stress response and NRF2 signaling pathway in autism spectrum disorder</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Davinelli</surname><given-names>Sergio</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Medoro</surname><given-names>Alessandro</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Siracusano</surname><given-names>Martina</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Savino</surname><given-names>Rosa</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Saso</surname><given-names>Luciano</given-names></name><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Scapagnini</surname><given-names>Giovanni</given-names></name><email>giovanni.scapagnini@unimol.it</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Mazzone</surname><given-names>Luigi</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><aff id="aff1"><label>a</label>Department of Medicine and Health Sciences "V. Tiberio", University of Molise, Campobasso, Italy</aff><aff id="aff2"><label>b</label>Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy</aff><aff id="aff3"><label>c</label>Child Neurology and Psychiatry Unit, Department of Wellbeing of Mental and Neurological, Dental and Sensory Organ Health, Policlinico Tor Vergata Hospital, Rome, Italy</aff><aff id="aff4"><label>d</label>Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy</aff><aff id="aff5"><label>e</label>Department of Physiology and Pharmacology &#x0201c;Vittorio Erspamer&#x0201d;, Sapienza University of Rome, Rome, Italy</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author. Department of Medicine and Health Sciences &#x0201c;V. Tiberio&#x0201d;, University of Molise, Via F. De Sanctis, s.n.c., Campobasso, 86100, Italy. <email>giovanni.scapagnini@unimol.it</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>02</day><month>5</month><year>2025</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>5</month><year>2025</year></pub-date><volume>83</volume><elocation-id>103661</elocation-id><history><date date-type="received"><day>10</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>30</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>1</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors. Published by Elsevier B.V.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><p>The prevalence of autism spectrum disorder (ASD), a neurodevelopmental disorder characterized by impairments in social communication and restricted/repetitive behavioral patterns, has increased significantly over the past few decades. The etiology of ASD involves a highly complex interplay of genetic, neurobiological, and environmental factors, contributing to significant heterogeneity in its clinical phenotype. In the evolving landscape of ASD research, increasing evidence suggests that oxidative stress, resulting from both intrinsic and extrinsic factors, may be a crucial pathophysiological driver in ASD, influencing neurodevelopmental processes that underlie behavioral abnormalities. Elevated levels of oxidative stress biomarkers, including lipid peroxides, protein oxidation products, and DNA damage markers, alongside deficient antioxidant enzyme activity, have been consistently linked to ASD. This may be attributed to dysregulated activity of nuclear factor erythroid 2-related factor 2 (NRF2), a pivotal transcription factor that maintains cellular redox homeostasis by orchestrating the expression of genes involved in antioxidant defenses. Here, we summarize the converging evidence that redox imbalance in ASD may result from NRF2 dysregulation, leading to reduced expression of its target genes. We also highlight the most promising antioxidant compounds under investigation, which may restore NRF2 activity and ameliorate ASD behavioral symptoms.</p></abstract><abstract abstract-type="author-highlights" id="abs0015"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Autism Spectrum Disorder (ASD) is a multifactorial condition caused by both genetic and non-genetic factors.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">Oxidative stress may contribute to ASD by affecting neurodevelopmental processes.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">ASD is linked to high oxidative markers and impaired antioxidant defences.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">NRF2 dysregulation may underlie redox imbalance observed in ASD.</p></list-item><list-item id="u0030"><label>&#x02022;</label><p id="p0030">Antioxidant compounds targeting NRF2 show therapeutic potential in ASD.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>NRF2</kwd><kwd>Autism</kwd><kwd>Oxidative stress</kwd><kwd>Inflammation</kwd><kwd>Antioxidants</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0040">According to the recent Global Burden of Disease Study 2021, autism spectrum disorder (ASD) affects approximately 61.8 million individuals worldwide, which translates to about 1 in every 127 people globally. Although this burden diminishes with increasing age, ASD was ranked within the top-ten causes of non-fatal health burden for people younger than 20 years [<xref rid="bib1" ref-type="bibr">1</xref>]. Phenotypically, ASD is a heterogeneous neurodevelopmental disorder characterized by a core set of symptoms, which include alterations in social interaction, deficits in communication, and the presence of restricted and repetitive behaviors, comprising sensory sensitivities [<xref rid="bib2" ref-type="bibr">2</xref>]. Beyond core symptoms, individuals with ASD may exhibit challenges in emotional regulation, cognitive and adaptive variability, which can range from intellectual impairment (requiring a high level of support needs) to high cognitive skills (requiring a low level of support needs) [<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib4" ref-type="bibr">4</xref>]. Although the exact etiology of the disorder remains unclear, the diverse clinical manifestations of ASD result from a complex interplay of genetic, neurobiological, and environmental factors [<xref rid="bib5" ref-type="bibr">5</xref>]. A number of genetic alterations, such as copy number variants (CNVs) and single nucleotide polymorphisms (SNP), may affect brain development processes, including cell adhesion, neural development, and synaptogenesis [<xref rid="bib6" ref-type="bibr">6</xref>]. Likewise, several signaling pathways, including phosphoinositide 3-kinase (PI3K)/Akt, mechanistic target of rapamycin (mTOR), and Wingless/Integrated (Wnt) signaling pathways, are frequently altered in various fetal and early postnatal stages of ASD phenotypes [<xref rid="bib7" ref-type="bibr">7</xref>]. These alterations can dysregulate neuronal differentiation and growth, lead to increased synthesis of inflammatory cytokines, and cause changes in dendritic spine density and synaptic pruning [<xref rid="bib8" ref-type="bibr">8</xref>]. Current evidence also suggests that there are several prenatal and perinatal environmental risk factors for ASD, including advanced parental age, maternal health conditions, birth complications, and prenatal chemical exposures [<xref rid="bib9" ref-type="bibr">9</xref>]. This array of environmental risk factors may interact with genetic predispositions, modifying neurodevelopmental trajectories through several mechanisms, including immune dysregulation, mitochondrial dysfunction, hormonal disruptions, gut microbiome alterations, and oxidative stress [<xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>].</p><p id="p0045">Recently, a number of studies have increasingly highlighted the significance of oxidative stress in the pathophysiology of ASD, suggesting an imbalance between the production of reactive oxygen species (ROS) and antioxidant defenses in both the periphery and the brain [<xref rid="bib13" ref-type="bibr">13</xref>]. Notably, elevated levels of reactive species result in genotoxicity and trigger a sterile inflammatory response, as well as microglial activation in the brain, contributing to the development of ASD. Indeed, redox imbalance has been consistently observed in children with ASD and appears to be associated with decreased plasma levels of reduced glutathione (GSH), a key endogenous antioxidant, and a lower ratio of GSH to oxidized glutathione (GSSG) [<xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>]. However, GSH levels are also significantly reduced in the cerebellum and temporal regions of the brain in individuals with ASD. This decline in GSH contributes to oxidative stress, neuroinflammation, and mitochondrial dysfunction, as indicated by increased levels of nitrosative and oxidative damage markers, including 3-nitrotyrosine (3-NT) and 8-oxo-deoxyguanosine (8-oxodG), elevated levels of 3-chlorotyrosine (3-CT), a recognized biomarker of chronic inflammation, and altered aconitase activity, a marker of mitochondrial superoxide production [<xref rid="bib16" ref-type="bibr">16</xref>,<xref rid="bib17" ref-type="bibr">17</xref>]. In addition to GSH, other endogenous antioxidants are altered in children with ASD, such as superoxide dismutase (SOD) and catalase (CAT), resulting in extensive oxidative damage to macromolecules, chronic inflammation, and abnormal neuronal cell function [<xref rid="bib18" ref-type="bibr">18</xref>,<xref rid="bib19" ref-type="bibr">19</xref>]. The dysregulation of the thioredoxin (Trx) system, a crucial component of cellular redox regulation, has also been linked to ASD, and its dysfunction may further compromise the ability to manage oxidative stress effectively [<xref rid="bib20" ref-type="bibr">20</xref>].</p><p id="p0050">A battery of cytoprotective genes encoding antioxidant enzymes is transcriptionally activated by nuclear factor erythroid 2-related factor 2 (NRF2) in response to oxidative/genotoxic stress. NRF2 is the major transcription factor sensitive to shifts in the redox status and coordinates the expression of a vast array of genes containing a specific motif (5&#x02032;-A/GTGAC//nnnGCA/G-3&#x02032;) in the promoter region that binds NRF2, known as the antioxidant response elements (AREs) [<xref rid="bib21" ref-type="bibr">21</xref>]. Accordingly, ARE-driven genes, such as <italic>SOD</italic>, heme oxygenase 1 (<italic>HO-1</italic>), glutathione peroxidase 2 (<italic>GPX2</italic>), glutamate-cysteine ligase (<italic>GCL</italic>), glutathione reductase (<italic>GR</italic>), thioredoxin reductase (<italic>TXNRD</italic>), and peroxiredoxins (<italic>PRXs</italic>), along with phase II xenobiotic detoxification enzymes, including NAD(P)H:quinone dehydrogenase 1 (<italic>NQO1</italic>), glutathione-S-transferases (<italic>GSTs</italic>), and UDP-glucuronosyltransferases (<italic>UGTs</italic>), are induced by NRF2 and alleviate oxidative stress and genotoxicity caused by reactive species and environmental factors (e.g., xenobiotics) [<xref rid="bib22" ref-type="bibr">22</xref>]. Given the association of redox imbalance with several neuropsychiatric disorders and the key role of the NRF2 pathway in counteracting oxidative stress, numerous studies continue to reveal the significant involvement of NRF2 in conditions such as major depressive disorder, bipolar disorder, schizophrenia, and attention deficit hyperactivity disorder (ADHD) [<xref rid="bib23" ref-type="bibr">23</xref>,<xref rid="bib24" ref-type="bibr">24</xref>].</p><p id="p0055">In the following sections, we first highlight the relevance of oxidative stress in ASD by examining how dysregulation of redox balance and alterations in oxidative stress biomarkers contribute to its pathophysiology. Next, we discuss recent developments concerning NRF2 in ASD, covering mechanistic aspects and summarizing the contributions of NRF2 and its target genes to the disorder. Finally, the article examines potential compounds that modulate NRF2 by enhancing the activity of its associated enzymes and that are currently under investigation.</p></sec><sec id="sec2"><label>2</label><title>Oxidative stress and ASD</title><p id="p0060">ASD has been increasingly associated with disruptions in redox homeostasis, where excessive ROS generation combined with impaired antioxidant defenses (i.e., oxidative stress), contributes to neuronal dysfunction and neuroinflammation [<xref rid="bib25" ref-type="bibr">25</xref>,<xref rid="bib26" ref-type="bibr">26</xref>]. As pleiotropic physiological signaling agents, ROS, particularly hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), regulate multiple molecular targets and cellular processes, including proliferation, differentiation, and adaptive responses to environmental stress (e.g., antioxidant defense). At low physiological levels, H<sub>2</sub>O<sub>2</sub> acts as a major signaling molecule by reversibly oxidizing specific protein targets, which modulates their activity, localization, and interactions [<xref rid="bib27" ref-type="bibr">[27]</xref>, <xref rid="bib28" ref-type="bibr">[28]</xref>, <xref rid="bib29" ref-type="bibr">[29]</xref>]. Unlike other ROS, H<sub>2</sub>O<sub>2</sub> is much more stable, enabling it to support controlled signaling rather than causing widespread damage. Its ability to cross biological membranes allows it to influence processes at sites distant from where it is produced. H<sub>2</sub>O<sub>2</sub> reacts mainly with cysteine residues in proteins, which supports the regulation of signaling pathways, such as NRF2 activity, without triggering the immediate and extensive damage characteristic of more reactive species (e.g., hydroxyl radicals). In addition, enzymatic redox systems regulate H<sub>2</sub>O<sub>2</sub> levels under normal conditions to maintain its signaling role within a safe and effective range [<xref rid="bib30" ref-type="bibr">[30]</xref>, <xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>].</p><p id="p0065">However, it should be noted that ROS is an umbrella term for oxygen-containing molecules, including free radicals (e.g., superoxide, hydroxyl, peroxyl) and non-radical oxidants (e.g., hydrogen peroxide, ozone, singlet oxygen), with distinct chemical reactivity that modulates their biological impact. Nevertheless, the pleiotropic actions of ROS, which are beneficial at low physiological concentrations (i.e., promoting cell proliferation, differentiation, and migration), may become detrimental under conditions characterized by increased ROS levels [<xref rid="bib29" ref-type="bibr">29</xref>]. The antagonistic pleiotropic effect of ROS is particularly relevant in the embryonic nervous system, where ROS influence neuronal polarity, neuronal connectivity, synaptic transmission, and neuronal network organization [<xref rid="bib35" ref-type="bibr">35</xref>]. For instance, it has been reported that H<sub>2</sub>O<sub>2</sub>, depending on its physiological concentration, may contribute to promoting axonal and neuronal growth. Conversely, a pathological increase in ROS levels, including H<sub>2</sub>O<sub>2</sub>, has been associated with growth cone collapse and axonal degeneration [<xref rid="bib36" ref-type="bibr">36</xref>]. In this context, maternal immune activation (MIA), a significant environmental risk factor linked to the development of ASD, has been reported to upregulate the expression of ROS-producing enzymes in the fetal brain, including NADPH oxidases (NOXs), the major endogenous enzymatic sources of superoxide anion radical (O<sub>2</sub>&#x000b7;<sup>-</sup>) and H<sub>2</sub>O<sub>2</sub>, leading to the loss of Purkinje cells and the development of ASD-like behaviors [<xref rid="bib37" ref-type="bibr">37</xref>]. Increased expression of NOXs, particularly the NOX2 isoform, has also been observed in B cells from children with ASD [<xref rid="bib38" ref-type="bibr">38</xref>].</p><p id="p0070">Cellular ROS are generated as inevitable byproducts of mitochondrial oxidative phosphorylation and by various enzymatic reactions, including those catalyzed by NOXs [<xref rid="bib39" ref-type="bibr">39</xref>]. Superoxide radicals are produced by both Complex I and Complex III of the mitochondrial electron transport chain and are rapidly dismuted by SOD into H<sub>2</sub>O<sub>2</sub>, which is then detoxified by CAT and GPX [<xref rid="bib19" ref-type="bibr">19</xref>]. These reactions maintain H<sub>2</sub>O<sub>2</sub> concentrations in the low nanomolar range, which is essential for redox signaling. Mitochondrial dysfunction has been consistently reported in ASD and is indicated by elevated lactate and pyruvate levels, reduced ATP production, and altered oxygen consumption and coupling efficiency. Impaired mitochondrial activity increases vulnerability to metabolic stress and has been linked to immune dysregulation and neuronal impairment, as shown by mitochondrial DNA abnormalities and defects in oxidative metabolic pathways. Mitochondrial inefficiency also affects the function of key antioxidant enzymes, including SOD, CAT, and GPX, leading to increased superoxide leakage, oxidative protein damage, chronic inflammation, and neuronal dysfunction [<xref rid="bib40" ref-type="bibr">[40]</xref>, <xref rid="bib41" ref-type="bibr">[41]</xref>, <xref rid="bib42" ref-type="bibr">[42]</xref>, <xref rid="bib43" ref-type="bibr">[43]</xref>] (<xref rid="fig1" ref-type="fig">Fig. 1</xref>).<fig id="fig1"><label>Fig. 1</label><caption><p><bold>Oxidative stress in the context of autism spectrum disorder</bold>. The figure depicts a shift from physiological ROS levels, essential for normal redox signaling, to excessive concentrations that promote cellular damage. Endogenous sources of ROS include mitochondrial oxidative phosphorylation, NADPH oxidases, oxidative enzymes, peroxisomal activity, and endoplasmic reticulum stress, alongside environmental factors, such as xenobiotic exposure. Increased levels of ROS, such as hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), superoxide (O<sub>2</sub>&#x02022;<sup>-</sup>), and hydroxyl radicals (&#x02022;OH), can cause oxidative damage to lipids, proteins, and DNA, affecting cellular homeostasis and neurodevelopment. These redox alterations are also associated with inflammatory activity at both systemic and brain levels. Overall, these processes impair neuronal and synaptic function, cause changes in dendritic spine density, and affect synaptic pruning. Together, these converging events contribute to the pathophysiology of autism spectrum disorder.</p></caption><alt-text id="alttext0010">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig></p><p id="p0075">Beyond mitochondrial sources, several non-mitochondrial enzymes also contribute to cellular ROS generation. The central nervous system (CNS) is highly dependent on O<sub>2</sub> and particularly sensitive to changes in its levels [<xref rid="bib44" ref-type="bibr">44</xref>]. For this reason, NOXs, which are localized to different cellular compartments, such as the plasma membrane and endoplasmic reticulum, are maintained at low levels in resting CNS cells, ensuring a stable and low flux of H<sub>2</sub>O<sub>2</sub>. This steady state allows H<sub>2</sub>O<sub>2</sub> to oxidize specific cysteine residues in target proteins, modulating the activity of key transcription factors (e.g., NRF2), receptor tyrosine kinases, and ion channels, which in turn promotes neuronal survival and differentiation [<xref rid="bib45" ref-type="bibr">45</xref>]. However, insults to the CNS, such as those occurring in ASD and associated with environmental factors (e.g., MIA and toxic exposures), neuroinflammation, mitochondrial dysfunction, and genetic factors, may lead to upregulation of NOX activity, increased oxidant production, and consequent oxidative damage [<xref rid="bib37" ref-type="bibr">37</xref>,<xref rid="bib38" ref-type="bibr">38</xref>,<xref rid="bib46" ref-type="bibr">[46]</xref>, <xref rid="bib47" ref-type="bibr">[47]</xref>, <xref rid="bib48" ref-type="bibr">[48]</xref>]. It has also been hypothesized, and partially supported by an observed association between peroxisomal biogenesis and ASD, that disturbances in peroxisomes may play a role in the pathophysiology of ASD. Peroxisomes are oxidative organelles that generate H<sub>2</sub>O<sub>2</sub> as a byproduct of various metabolic reactions, including fatty acid &#x003b2;-oxidation and amino acid catabolism [<xref rid="bib49" ref-type="bibr">[49]</xref>, <xref rid="bib50" ref-type="bibr">[50]</xref>, <xref rid="bib51" ref-type="bibr">[51]</xref>]. Recently, the kynurenine pathway, the major pathway of tryptophan catabolism and a key source of nicotinamide adenine dinucleotide (NAD<sup>+</sup>), has gained increasing attention in the context of ASD. Several metabolites associated with the kynurenine pathway possess pro-oxidant properties that may directly contribute to oxidative stress or exacerbate it in susceptible individuals with ASD [<xref rid="bib52" ref-type="bibr">52</xref>]. Notably, 3-hydroxykynurenine (3-HK) promotes ROS generation through auto-oxidation and interaction with transition metals, while quinolinic acid (QA) induces lipid peroxidation and depletes cellular antioxidants. Notably, 3-HK is a direct precursor to QA within the kynurenine pathway, as it is converted to 3-hydroxyanthranilic acid and subsequently to QA. This biochemical link suggests that elevated 3-HK may contribute to oxidative stress both directly and indirectly, by increasing QA levels and amplifying excitotoxic and oxidative damage [<xref rid="bib53" ref-type="bibr">53</xref>,<xref rid="bib54" ref-type="bibr">54</xref>]. It has also been demonstrated that MIA increases 3-HK and ROS levels in both the placenta and fetal brain of animal models, potentially contributing to the development of neuropsychiatric disorders such as ASD [<xref rid="bib55" ref-type="bibr">55</xref>].</p></sec><sec id="sec3"><label>3</label><title>Oxidative stress biomarkers in ASD</title><p id="p0080">From a clinical standpoint, multiple classes of biomarkers exhibit significant differences compared with neurotypical controls, suggesting the involvement of oxidative stress and impaired antioxidant defenses in ASD. Elevated levels of lipid peroxidation markers, protein oxidation biomarkers, DNA oxidation products, and altered antioxidant enzyme activity have been consistently reported across several clinical studies (<xref rid="tbl1" ref-type="table">Table 1</xref>). 8-Iso-prostaglandin F<sub>2</sub>&#x003b1; (8-iso-PGF<sub>2</sub>&#x003b1;), an isoprostane formed through the non-enzymatic peroxidation of arachidonic acid in cell membranes, is recognized as the clinical gold standard for assessing lipid oxidative stress in vivo. Several studies have reported elevated plasma and urinary levels of 8-iso-PGF<sub>2</sub>&#x003b1; in children with ASD [<xref rid="bib56" ref-type="bibr">[56]</xref>, <xref rid="bib57" ref-type="bibr">[57]</xref>, <xref rid="bib58" ref-type="bibr">[58]</xref>, <xref rid="bib59" ref-type="bibr">[59]</xref>]. Likewise, elevated malondialdehyde (MDA) levels, a product of polyunsaturated fatty acid (PUFA) peroxidation in cell membranes, have been observed in the frontal brain regions of individuals with ASD, as well as in the plasma and serum of children with ASD [<xref rid="bib18" ref-type="bibr">18</xref>,<xref rid="bib60" ref-type="bibr">[60]</xref>, <xref rid="bib61" ref-type="bibr">[61]</xref>, <xref rid="bib62" ref-type="bibr">[62]</xref>, <xref rid="bib63" ref-type="bibr">[63]</xref>, <xref rid="bib64" ref-type="bibr">[64]</xref>, <xref rid="bib65" ref-type="bibr">[65]</xref>, <xref rid="bib66" ref-type="bibr">[66]</xref>, <xref rid="bib67" ref-type="bibr">[67]</xref>]. Although few studies have focused on 4-hydroxynonenal (4-HNE), a major aldehyde product of the peroxidation of omega-6 PUFA, including linoleic and arachidonic acids, elevated levels have been reported in individuals with ASD, suggesting its potential as a peripheral biomarker of lipid peroxidation [<xref rid="bib68" ref-type="bibr">68</xref>,<xref rid="bib69" ref-type="bibr">69</xref>]. Protein carbonyls, which result from the introduction of carbonyl groups into the protein structure, are among the most widely used biomarkers for assessing protein oxidation. This modification can occur through the direct oxidation of amino acid side chains or reactions with lipid peroxidation products. Elevated carbonyl levels in two proteins involved in the complement system and immunoregulation have been found in the plasma of autistic children [<xref rid="bib70" ref-type="bibr">70</xref>]. Protein oxidation has also been reported in the cerebellum and other specific brain regions of individuals with ASD by Sajdel-Sulkowska et al., showing increased levels of 3-NT, which is formed by the reaction of superoxide with nitric oxide (NO) on tyrosine residues in proteins [<xref rid="bib71" ref-type="bibr">71</xref>,<xref rid="bib72" ref-type="bibr">72</xref>]. Multiple studies have demonstrated elevated levels of NO, nitrite, and peroxynitrite (ONOO<sup>&#x02212;</sup>) in individuals with ASD. For instance, plasma nitrite concentrations in children with ASD have been reported to be 1.38-fold higher than in controls [<xref rid="bib73" ref-type="bibr">73</xref>,<xref rid="bib74" ref-type="bibr">74</xref>]. NO is synthesized by nitric oxide synthase (NOS) using tetrahydrobiopterin (BH<sub>4</sub>) as a cofactor. Under conditions of BH<sub>4</sub> deficiency, NOS becomes uncoupled, leading to the production of peroxynitrite, a highly reactive nitrogen species (RNS), rather than NO. This uncoupling has been closely linked to mitochondrial dysfunction, a frequently observed feature in ASD [<xref rid="bib75" ref-type="bibr">75</xref>]. Both NO and peroxynitrite negatively affect mitochondrial function by inhibiting electron transport chain activity, thereby impairing ATP production and enhancing oxidative damage. It has been demonstrated that lymphoblastoid cell lines (LCLs) derived from individuals with ASD exhibit increased vulnerability to NO-induced mitochondrial dysfunction, suggesting that ASD LCLs may have intrinsic deficiencies in mitigating nitrosative stress [<xref rid="bib76" ref-type="bibr">76</xref>].<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Biomarkers of oxidative stress and antioxidant defense in autism spectrum disorder.</p></caption><alt-text id="alttext0020">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Biomarkers</th><th>Sample type</th><th>Method</th><th>Population</th><th>Results</th><th>Study</th></tr></thead><tbody><tr><td align="left">8-iso-PGF<sub>2</sub>&#x003b1;</td><td align="left">Urine</td><td align="left">ELISA</td><td align="left">ASD (n&#x000a0;=&#x000a0;21) vs. NT (n&#x000a0;=&#x000a0;20), age 5&#x02013;12</td><td align="left">&#x02191; 8-iso-PGF<sub>2</sub>&#x003b1; in ASD</td><td align="left">[<xref rid="bib56" ref-type="bibr">56</xref>]</td></tr><tr><td align="left">8-iso-PGF<sub>2</sub>&#x003b1;</td><td align="left">Urine</td><td align="left">ELISA</td><td align="left">ASD (n&#x000a0;=&#x000a0;33), NT (n&#x000a0;=&#x000a0;29); age 4&#x02013;17</td><td align="left">&#x02191; 8-iso-PGF<sub>2</sub>&#x003b1; in ASD</td><td align="left">[<xref rid="bib59" ref-type="bibr">59</xref>]</td></tr><tr><td align="left">8-iso-PGF<sub>2</sub>&#x003b1;</td><td align="left">Serum</td><td align="left">ELISA</td><td align="left">ASD (n&#x000a0;=&#x000a0;24) vs. NT (n&#x000a0;=&#x000a0;24), age 9&#x02013;10</td><td align="left">&#x02191; 8-iso-PGF<sub>2</sub>&#x003b1; in ASD</td><td align="left">[<xref rid="bib57" ref-type="bibr">57</xref>]</td></tr><tr><td align="left">MDA</td><td align="left">Plasma</td><td align="left">TBARS assay</td><td align="left">ASD (n&#x000a0;=&#x000a0;30) vs. NT (n&#x000a0;=&#x000a0;30), age 3&#x02013;15</td><td align="left">&#x02191; MDA in ASD</td><td align="left">[<xref rid="bib62" ref-type="bibr">62</xref>]</td></tr><tr><td align="left">MDA</td><td align="left">Plasma</td><td align="left">Spectrophotometric</td><td align="left">ASD (n&#x000a0;=&#x000a0;52) vs. NT (n&#x000a0;=&#x000a0;48), age 3&#x02013;6</td><td align="left">&#x02191; MDA in ASD</td><td align="left">[<xref rid="bib18" ref-type="bibr">18</xref>]</td></tr><tr><td align="left">MDA</td><td align="left">Plasma</td><td align="left">TBA assay</td><td align="left">ASD (n&#x000a0;=&#x000a0;9) vs. NT (n&#x000a0;=&#x000a0;2), age 6</td><td align="left">&#x02191; MDA in ASD</td><td align="left">[<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr><tr><td align="left">MDA</td><td align="left">Plasma</td><td align="left">ELISA</td><td align="left">ASD (n&#x000a0;=&#x000a0;30) vs. NT (n&#x000a0;=&#x000a0;30), age 3&#x02013;11</td><td align="left">&#x02191; MDA in ASD</td><td align="left">[<xref rid="bib66" ref-type="bibr">66</xref>]</td></tr><tr><td align="left">MDA</td><td align="left">Plasma</td><td align="left">N/A</td><td align="left">ASD (n&#x000a0;=&#x000a0;19) vs. NT (n&#x000a0;=&#x000a0;19), age N/A</td><td align="left">&#x02191; MDA in ASD</td><td align="left">[<xref rid="bib63" ref-type="bibr">63</xref>]</td></tr><tr><td align="left">MDA</td><td align="left">Frontal cortex (postmortem)</td><td align="left">Immunofluorescence</td><td align="left">ASD (n&#x000a0;=&#x000a0;5), dup(15q/ASD) (n&#x000a0;=&#x000a0;5) vs. NT (n&#x000a0;=&#x000a0;5), age 7&#x02013;32</td><td align="left">&#x02191; MDA in ASD</td><td align="left">[<xref rid="bib60" ref-type="bibr">60</xref>]</td></tr><tr><td align="left">MDA</td><td align="left">Serum</td><td align="left">Not specified</td><td align="left">ASD (n&#x000a0;=&#x000a0;45) vs. NT (n&#x000a0;=&#x000a0;42), age 3&#x02013;11</td><td align="left">&#x02191; MDA in ASD</td><td align="left">[<xref rid="bib65" ref-type="bibr">65</xref>]</td></tr><tr><td align="left">MDA</td><td align="left">Plasma</td><td align="left">TBARS assay</td><td align="left">ASD (n&#x000a0;=&#x000a0;35) vs. NT (n&#x000a0;=&#x000a0;34), age 7&#x02013;17</td><td align="left">&#x02191; MDA in ASD</td><td align="left">[<xref rid="bib67" ref-type="bibr">67</xref>]</td></tr><tr><td align="left">4-HNE</td><td align="left">Urine</td><td align="left">Spectrophotometric</td><td align="left">ASD (n&#x000a0;=&#x000a0;45) vs. NT (n&#x000a0;=&#x000a0;50), age 4&#x02013;12</td><td align="left">&#x02191; 4-HNE in ASD</td><td align="left">[<xref rid="bib68" ref-type="bibr">68</xref>]</td></tr><tr><td align="left">4-HNE</td><td align="left">Plasma and erythrocyte membrane</td><td align="left">Western blot</td><td align="left">ASD (n&#x000a0;=&#x000a0;20) vs. NT (n&#x000a0;=&#x000a0;18), age 4&#x02013;30</td><td align="left">&#x02191; 4-HNE in ASD</td><td align="left">[<xref rid="bib69" ref-type="bibr">69</xref>]</td></tr><tr><td align="left">Protein carbonyls (C8A, Igkc)</td><td align="left">Plasma</td><td align="left">2D-Oxyblot&#x000a0;+&#x000a0;Western blot</td><td align="left">ASD (n&#x000a0;=&#x000a0;15) vs. NT (n&#x000a0;=&#x000a0;15), age 2&#x02013;6</td><td align="left">&#x02191; protein carbonyls in ASD</td><td align="left">[<xref rid="bib70" ref-type="bibr">70</xref>]</td></tr><tr><td align="left">3-NT</td><td align="left">Cerebellum (postmortem)</td><td align="left">ELISA</td><td align="left">ASD (n&#x000a0;=&#x000a0;5) vs. NT (n&#x000a0;=&#x000a0;3), age 5&#x02013;32</td><td align="left">&#x02191; 3-NT in ASD</td><td align="left">[<xref rid="bib72" ref-type="bibr">72</xref>]</td></tr><tr><td align="left">3-NT</td><td align="left">Multiple brain regions (postmortem)</td><td align="left">ELISA</td><td align="left">ASD (n&#x000a0;=&#x000a0;2) vs. NT (n&#x000a0;=&#x000a0;2), age 8.8&#x02013;14.6</td><td align="left">&#x02191; 3-NT in ASD</td><td align="left">[<xref rid="bib71" ref-type="bibr">71</xref>]</td></tr><tr><td align="left">8-oxodG in cfDNA</td><td align="left">Plasma (cfDNA)</td><td align="left">Immunodot blot</td><td align="left">ASD (n&#x000a0;=&#x000a0;133) vs. NT (n&#x000a0;=&#x000a0;27), age 4&#x02013;12</td><td align="left">&#x02191; 8-oxodG in severe ASD group</td><td align="left">[<xref rid="bib77" ref-type="bibr">77</xref>]</td></tr><tr><td align="left">8-oxodG</td><td align="left">Serum</td><td align="left">ELISA</td><td align="left">ASD (n&#x000a0;=&#x000a0;60) vs. NT (n&#x000a0;=&#x000a0;29), age 3&#x02013;20</td><td align="left">&#x02191; 8-oxodG in ASD</td><td align="left">[<xref rid="bib78" ref-type="bibr">78</xref>]</td></tr><tr><td align="left">8-oxo-dG</td><td align="left">Lymphocytes</td><td align="left">LC-MS-MS</td><td align="left">ASD (n&#x000a0;=&#x000a0;84), age 3&#x02013;18</td><td align="left">&#x02193; 8-oxo-dG in CC genotype vs. T+ carriers (NRF2 SNP)</td><td align="left">[<xref rid="bib118" ref-type="bibr">118</xref>]</td></tr><tr><td align="left">Nitrite, GPX, SOD</td><td align="left">Plasma (nitrite in erythrocyte)</td><td align="left">Colorimetric assay</td><td align="left">ASD (n&#x000a0;=&#x000a0;27) vs. NT (n&#x000a0;=&#x000a0;30), age 2&#x02013;13</td><td align="left">&#x02191; Nitrite and &#x02191; GPX in ASD, = SOD</td><td align="left">[<xref rid="bib74" ref-type="bibr">74</xref>]</td></tr><tr><td align="left">GSH, GSSG, GSH/GSSG ratio</td><td align="left">Plasma</td><td align="left">HPLC</td><td align="left">ASD (n&#x000a0;=&#x000a0;43) vs. NT (n&#x000a0;=&#x000a0;41), age 3&#x02013;10</td><td align="left">&#x02193; GSH, &#x02193; GSH/GSSG, &#x02191; GSSG in ASD</td><td align="left">[<xref rid="bib80" ref-type="bibr">80</xref>]</td></tr><tr><td align="left">GSH, GSSG, GSH/GSSG ratio</td><td align="left">Cerebellum (postmortem)</td><td align="left">HPLC</td><td align="left">ASD (n&#x000a0;=&#x000a0;15) vs. NT (n&#x000a0;=&#x000a0;12), age N/A</td><td align="left">&#x02193; GSH, &#x02193; GSH/GSSG, &#x02191; GSSG in ASD</td><td align="left">[<xref rid="bib17" ref-type="bibr">17</xref>]</td></tr><tr><td align="left">GSH, GSSG, GSH/GSSG ratio</td><td align="left">Plasma</td><td align="left">HPLC</td><td align="left">ASD (n&#x000a0;=&#x000a0;55) vs. NT (n&#x000a0;=&#x000a0;44), age 5&#x02013;16</td><td align="left">&#x02193; GSH, &#x02193; GSH/GSSG, &#x02191; GSSG in ASD</td><td align="left">[<xref rid="bib81" ref-type="bibr">81</xref>]</td></tr><tr><td align="left">GST</td><td align="left">Blood</td><td align="left">Genotyping</td><td align="left">ASD (n&#x000a0;=&#x000a0;113), age N/A</td><td align="left">GST polymorphisms associated with ASD severity</td><td align="left">[<xref rid="bib82" ref-type="bibr">82</xref>]</td></tr><tr><td align="left">SOD, CAT</td><td align="left">Erythrocytes</td><td align="left">Spectrophotometry</td><td align="left">ASD (n&#x000a0;=&#x000a0;52) vs. NT (n&#x000a0;=&#x000a0;48), age 3&#x02013;6</td><td align="left">&#x02191; SOD and &#x02191; CAT in ASD</td><td align="left">[<xref rid="bib18" ref-type="bibr">18</xref>]</td></tr><tr><td align="left">SOD</td><td align="left">Serum</td><td align="left">Colorimetric assay</td><td align="left">ASD (n&#x000a0;=&#x000a0;96) vs. NT (n&#x000a0;=&#x000a0;96), age N/A</td><td align="left">&#x02193; SOD in ASD</td><td align="left">[<xref rid="bib83" ref-type="bibr">83</xref>]</td></tr><tr><td align="left">GSH, GSSG, GSH/GSSG ratio, SOD, CAT, GPX</td><td align="left">Plasma (SOD &#x00026; CAT in erythrocyte)</td><td align="left">Spectrophotometry</td><td align="left">ASD (n&#x000a0;=&#x000a0;30) vs. NT (n&#x000a0;=&#x000a0;30), age 3&#x02013;15</td><td align="left">&#x02193; GSH, &#x02191; GSSG, &#x02191; SOD, and &#x02191; GPX in ASD, = CAT</td><td align="left">[<xref rid="bib62" ref-type="bibr">62</xref>]</td></tr><tr><td align="left">SOD, CAT</td><td align="left">Plasma</td><td align="left">Enzyme activity assay</td><td align="left">ASD (n&#x000a0;=&#x000a0;10) vs. siblings (n&#x000a0;=&#x000a0;10), age 4&#x02013;10</td><td align="left">&#x02193; SOD, &#x02191; CAT, &#x02193; SOD/CAT ratio in ASD</td><td align="left">[<xref rid="bib19" ref-type="bibr">19</xref>]</td></tr><tr><td align="left">SOD, CAT</td><td align="left">Erythrocytes</td><td align="left">Spectrophotometry</td><td align="left">ASD (n&#x000a0;=&#x000a0;27) vs. NT (n&#x000a0;=&#x000a0;26), age N/A</td><td align="left">&#x02191; SOD, &#x02193; CAT in ASD</td><td align="left">[<xref rid="bib84" ref-type="bibr">84</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: 8-Iso-prostaglandin F<sub>2</sub>&#x003b1;, 8-iso-PGF<sub>2</sub>&#x003b1;; Enzyme-linked immunosorbent assay, ELISA; Autism spectrum disorder, ASD; Neurotypical, NT; Malondialdehyde, MDA; Thiobarbituric acid reactive substances, TBARS; Thiobarbituric acid, TBA; Not available, N/A; Duplication, dup; 4-Hydroxynonenal, 4-HNE; Complement component 8 alpha chain, C8A; Igkc Immunoglobulin kappa constant region; 3-Nitrotyrosine, 3-NT; 8-oxo-deoxyguanosine, 8-oxodG; cell free DNA, cfDNA; Liquid Chromatography with tandem mass spectrometry, LC-MS-MS; Nuclear factor erythroid 2-related factor 2, NRF2; Single-nucleotide polymorphism, SNP; Glutathione, GSH; Glutathione disulfide GSSG; High-performance liquid chromatography, HPLC; Glutathione S-Transferase, GST; Superoxide Dismutase, SOD; Catalase, CAT; Glutathione peroxidase, GPX.</p></fn></table-wrap-foot></table-wrap></p><p id="p0085">Recently, emerging evidence suggests that DNA oxidation may play a significant role in the pathogenesis of ASD by influencing gene expression, epigenetic regulation, and neuronal integrity. For example, it has been reported that oxidized cell-free DNA (cfDNA) obtained from the blood of individuals with ASD acts as a stress-signaling factor, triggering a chronic inflammatory process. Moreover, cfDNA from patients with severe ASD was characterized by a high abundance of oxidative modifications, specifically measured as 8-oxodG [<xref rid="bib77" ref-type="bibr">77</xref>]. Substantial oxidative damage to DNA in individuals with ASD has also been demonstrated in other studies, where serum 8-oxodG levels were found to be significantly higher in autistic children [<xref rid="bib65" ref-type="bibr">65</xref>,<xref rid="bib78" ref-type="bibr">78</xref>].</p><p id="p0090">The endogenous antioxidant defense system, in particular GSH, appears to be dysregulated in ASD. GSH can neutralize hydroxyl radicals and hydrogen peroxide through its thiol group but also serves as a cofactor for antioxidant enzymes, such as GPX, which reduces peroxides to water or alcohol, thus protecting cells from oxidative damage. The balance between reduced GSH and its oxidized form GSSG is a marker of oxidative stress, with a higher GSH/GSSG ratio indicating better antioxidant capacity [<xref rid="bib79" ref-type="bibr">79</xref>]. A large meta-analysis found that children with autism have lower levels of GSH, total glutathione (tGSH), and GSH/GSSG ratio, along with higher GSSG, indicating a shift toward an oxidized redox state [<xref rid="bib16" ref-type="bibr">16</xref>]. This reduction in glutathione redox capacity has been linked to impaired mitochondrial enzyme activity (e.g., decreased aconitase activity), excess mitochondrial superoxide production, neuroinflammation, immune dysregulation, and oxidative damage to macromolecules [<xref rid="bib17" ref-type="bibr">17</xref>,<xref rid="bib80" ref-type="bibr">80</xref>]. Importantly, glutathione redox imbalance in ASD has been shown to correlate with ASD severity. For instance, autistic children have 21&#x000a0;% lower GSH levels and a 49&#x000a0;% higher GSSG/GSH ratio than controls, and these oxidative stress markers were among the biochemical differences associated with more severe language and social impairment [<xref rid="bib81" ref-type="bibr">81</xref>]. Moreover, specific GST polymorphisms have been linked to more severe ASD symptoms and lower adaptive functioning, suggesting that genetic factors influencing glutathione metabolism may affect the clinical presentation of ASD [<xref rid="bib82" ref-type="bibr">82</xref>].</p><p id="p0095">Other studies on endogenous antioxidant enzymes, such as SOD and CAT, which are considered potential biomarkers of oxidative stress, have reported conflicting results. SOD and CAT activity has been found to be higher in erythrocytes from individuals with ASD compared to controls, which may reflect a compensatory response to elevated oxidative stress levels [<xref rid="bib18" ref-type="bibr">18</xref>]. However, a case-control study reported decreased serum SOD levels in ninety-six children with ASD [<xref rid="bib83" ref-type="bibr">83</xref>]. Interestingly, other findings indicate that serum CAT is elevated in individuals with ASD, while CAT activity in red blood cells (RBCs) is reduced in autistic children. This discrepancy may reflect tissue-specific differences in antioxidant responses, as well as differences in the underlying etiology of ASD and neurodevelopmental stage. Moreover, it has also been observed that the SOD/CAT ratio is often decreased due to altered CAT activity [<xref rid="bib19" ref-type="bibr">19</xref>,<xref rid="bib62" ref-type="bibr">62</xref>,<xref rid="bib84" ref-type="bibr">84</xref>].</p></sec><sec id="sec4"><label>4</label><title>Oxidative and nitrosative stress in synaptic dysfunction and ASD</title><p id="p0100">Oxidative and nitrosative stress are increasingly recognized as key contributors to the pathogenesis of ASD, particularly in the context of synaptic dysfunction. They converge on synaptic processes through multiple mechanisms, including direct protein modifications, mitochondrial impairment, and disrupted neurotransmitter dynamics, which together compromise the fidelity of synaptic signaling. The resulting synaptic impairments provide a mechanistic link between cellular stress and the complex behavioral features associated with ASD [<xref rid="bib85" ref-type="bibr">85</xref>]. One of the mechanisms through which nitrosative stress affects synaptic function involves posttranslational modifications of proteins. Peroxynitrite, a potent RNS formed by the reaction of NO with superoxide, can nitrate tyrosine residues in proteins, leading to the accumulation of 3-NT. As mentioned above, elevated levels of 3-NT have been reported in individuals with ASD, indicating extensive protein alterations in the brain. These nitrosative modifications interfere with the structure and function of critical synaptic proteins, impairing neurotransmission, synaptic vesicle trafficking, ion channel activity, and postsynaptic receptor clustering [<xref rid="bib71" ref-type="bibr">71</xref>]. Another important nitrosative mechanism is S-nitrosylation, the covalent attachment of NO to cysteine thiol groups, which alters the structure and function of proteins involved in synaptic plasticity [<xref rid="bib73" ref-type="bibr">73</xref>,<xref rid="bib86" ref-type="bibr">86</xref>]. While physiological S-nitrosylation regulates processes, such as glutamate receptor modulation and mitochondrial dynamics, excessive NO levels in ASD affect synaptogenesis as well as the glutamatergic and GABAergic systems in the cortex and the striatum, contributing to ASD-like behavioral features [<xref rid="bib87" ref-type="bibr">87</xref>]. Moreover, aberrant S-nitrosylation of proteins, such as dynamin-related protein 1 (Drp1), exacerbates mitochondrial fission, impairing energy production and calcium buffering, both essential for synaptic vesicle cycling and neurotransmitter release [<xref rid="bib88" ref-type="bibr">[88]</xref>, <xref rid="bib89" ref-type="bibr">[89]</xref>, <xref rid="bib90" ref-type="bibr">[90]</xref>].</p><p id="p0105">Peroxynitrite and other RNS damage mitochondrial components, impair oxidative phosphorylation, and promote further production of ROS and RNS, establishing a feedback loop that exacerbates cellular stress. Mitochondrial dysfunction consequently compromises ATP generation, which is essential for synaptic vesicle cycling and efficient neurotransmission. Indeed, this energy deficit has been reported to contribute to synaptic dysfunction in ASD, linking mitochondrial impairment to its neuropathological features [<xref rid="bib85" ref-type="bibr">85</xref>,<xref rid="bib91" ref-type="bibr">91</xref>].</p><p id="p0110">Long-term potentiation (LTP), which underlies learning and memory, is particularly vulnerable to oxidative and nitrosative stress [<xref rid="bib92" ref-type="bibr">92</xref>]. LTP, a process dependent on glutamate receptor activation and calcium signaling, is reduced in ASD due to oxidative inactivation of NMDA receptors and nitrosylation of proteins involved in dendritic spine remodeling [<xref rid="bib93" ref-type="bibr">93</xref>]. Likewise, excessive ROS and RNS alter the balance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission. Moreover, oxidative damage to glutamate transporters prolongs synaptic glutamate exposure, promoting excitotoxicity [<xref rid="bib94" ref-type="bibr">94</xref>,<xref rid="bib95" ref-type="bibr">95</xref>]. Conversely, nitrosative stress reduces the expression of glutamic acid decarboxylase (GAD), the enzyme that converts glutamate to GABA. Accordingly, the reduction in GABA synthesis leads to an imbalance in the excitatory-inhibitory neurotransmitter balance, shifting towards hyperexcitability, a pattern consistently reported in ASD neurobiology [<xref rid="bib96" ref-type="bibr">96</xref>,<xref rid="bib97" ref-type="bibr">97</xref>]. These converging redox-driven alterations in synaptic signaling, plasticity, and neurotransmitter balance may collectively contribute to the core neurobehavioral manifestations of ASD, including cognitive inflexibility, sensory hypersensitivity, and social communication deficits.</p></sec><sec id="sec5"><label>5</label><title>NRF2 signaling pathway: an overview</title><p id="p0115">Eukaryotic organisms have evolved sophisticated strategies to counteract oxidative and electrophilic stress resulting from metabolism or xenobiotic exposure. NRF2 is a versatile transcription factor that regulates a broad network of detoxification and antioxidant genes. Human NRF2 consists of seven NRF2&#x02013;ECH homology domains (Neh1&#x02013;7). The DLG and ETGE motifs in Neh2 interact with Kelch-like ECH-associated protein 1 (KEAP1), while Neh1 contains a basic-region leucine zipper (bZIP) motif that recognizes AREs in target gene promoters [<xref rid="bib98" ref-type="bibr">98</xref>,<xref rid="bib99" ref-type="bibr">99</xref>]. The importance of the NRF2 pathway in cellular homeostasis has led to its highly regulated control, with KEAP1 acting as its main regulator.</p><p id="p0120">The &#x0201c;hinge and latch&#x0201d; model describes how structural changes in KEAP1 influence the capture or release of NRF2. Under basal conditions, KEAP1 maintains the correct conformation and forms a complex with Cullin 3 (Cul3) and RING box protein 1 (Rbx1) to bind NRF2 and direct it toward proteasomal degradation [<xref rid="bib100" ref-type="bibr">100</xref>]. However, in addition to this canonical pathway, other mechanisms also regulate NRF2 (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). Glycogen synthase kinase-3&#x003b2; (GSK-3&#x003b2;), for example, phosphorylates NRF2 at specific sites, enhancing its interaction with &#x003b2;-transducin repeat-containing protein (&#x003b2;-TrCP), which in turn forms a complex with S-phase kinase-associated protein 1 (Skp1), Cullin 1 (Cul1), and Rbx1 to ubiquitinate and degrade NRF2 [<xref rid="bib101" ref-type="bibr">101</xref>,<xref rid="bib102" ref-type="bibr">102</xref>]. Conversely, protein kinase C (PKC) isoenzymes, casein kinase 2 (CK2), and AMP-activated protein kinase (AMPK) may positively regulate NRF2 activity by phosphorylating distinct sites [<xref rid="bib103" ref-type="bibr">103</xref>]. The role of KEAP1 is not limited to inhibiting NRF2 activity. It functions as a redox sensor that detects oxidative and electrophilic changes through specific cysteine residues containing thiol groups. Among these, the cysteine residues C151, C273, and C288 are highly reactive and susceptible to covalent modifications by low-level ROS and other electrophiles. When these thiol residues are modified, KEAP1 can no longer interact with the DLG motif, preventing complex formation with Cul3/Rbx1 and, consequently, NRF2 proteasomal degradation [<xref rid="bib104" ref-type="bibr">104</xref>].<fig id="fig2"><label>Fig. 2</label><caption><p><bold>Canonical and non-canonical regulation of NRF2 stability and activity</bold>. Under homeostatic conditions, NRF2 is constitutively ubiquitinated by the KEAP1&#x02013;CUL3&#x02013;RBX1 E3 ligase complex and degraded via the proteasome. Oxidative or electrophilic stress modifies reactive cysteines on KEAP1, impairing NRF2 ubiquitination and allowing its nuclear translocation. Instead of KEAP1, NRF2 can also be regulated through GSK-3&#x003b2;&#x02013;mediated phosphorylation, which targets NRF2 for &#x003b2;-TrCP&#x02013;dependent ubiquitination via the CUL1&#x02013;RBX1 complex. Likewise, phosphorylation by kinases such as AMPK, CK2, and PKC enhances NRF2 stability and promotes its nuclear accumulation. In the nucleus, NRF2 heterodimerizes with small Maf proteins and binds to AREs, inducing transcription of cytoprotective genes including HO-1, NQO1, SOD, CAT, and enzymes involved in glutathione synthesis and the pentose phosphate pathway (e.g., GCLC, GCLM, G6PD, 6PGD, ME1, IDH1). These pathways collectively orchestrate adaptive responses to maintain cellular redox homeostasis.</p></caption><alt-text id="alttext0015">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p><p id="p0125">Transport mediated by karyopherin &#x003b1;1 (importin &#x003b1;5) and karyopherin &#x003b2;1 (importin &#x003b2;1) is a critical process that promotes the translocation of newly synthesized NRF2 into the nucleus, where it binds to ARE sequences and induces NRF2-dependent gene expression [<xref rid="bib105" ref-type="bibr">105</xref>]. ARE motifs are located in several promoter regions encoding antioxidant and detoxifying enzymes, allowing NRF2 to coordinate a wide-ranging cytoprotective response. This NRF2-mediated transcription depends on various cofactors. Small maf proteins interact with NRF2 in recognizing ARE sequences [<xref rid="bib106" ref-type="bibr">106</xref>]. Likewise, CREB-binding protein (CBP)/p300 and the SUMO-conjugating enzyme UBC9 possess acetyltransferase and SUMOylation activities, respectively, which modulate promoter-specific DNA binding and play a significant role in the regulation of NRF2 activity. These post-translational modifications influence the function of CBP/p300 as transcriptional coactivators, thereby affecting NRF2-mediated gene expression and the cellular antioxidant response [<xref rid="bib107" ref-type="bibr">107</xref>,<xref rid="bib108" ref-type="bibr">108</xref>]. Additional transcription factors, such as Jun-D, c-Jun, Jun-B, activating transcription factors 3 and 4 (ATF3, ATF4), receptor-associated coactivator 3 (RAC3), runt-related transcription factor 2 (Runx2), and Yin Yang 1 (YY1), further enhance NRF2-driven transcription [<xref rid="bib109" ref-type="bibr">109</xref>]. Many genes regulated by NRF2 are critical for restoring redox balance and detoxifying in response to low-to-moderate levels of ROS, particularly SOD, CAT, HO-1, and NQO1. Additionally, NRF2 may increase NADPH levels by regulating glucose-6-phosphate dehydrogenase (<italic>G6PD</italic>), 6-phosphogluconate dehydrogenase (<italic>6PGD</italic>), malic enzyme 1 (<italic>ME1</italic>), and isocitrate dehydrogenase 1 (<italic>IDH1</italic>) [<xref rid="bib110" ref-type="bibr">110</xref>]. NADPH provides reducing equivalents for numerous antioxidant reactions and supports various cellular processes involved in oxidative stress defense, particularly through GSH. NRF2 also regulates the GSH system by controlling the expression of enzymes required for its synthesis, including glutamate-cysteine ligase (<italic>GCLC</italic> and <italic>GCLM</italic>), GR, GPX, and GSTs. The coordinated regulation of these enzymes maintains glutathione recycling and function, contributing to cellular redox balance and enhancing overall antioxidant capacity [<xref rid="bib111" ref-type="bibr">111</xref>]. Moreover, NRF2 contributes to redox restoration following oxidative stress by coordinating the expression of Trx, <italic>TXNRD1</italic>, and <italic>PRX</italic> genes [<xref rid="bib22" ref-type="bibr">22</xref>].</p><p id="p0130">When oxidative stress increases, the crosstalk between the NRF2 and nuclear factor kappa B (NF-&#x003ba;B) pathways plays a crucial role in regulating cellular responses to oxidative stress and inflammation. NF-&#x003ba;B induces the expression of proinflammatory mediators, whereas NRF2 counteracts NF-&#x003ba;B activity both directly and indirectly [<xref rid="bib112" ref-type="bibr">112</xref>]. These two factors compete for binding to CBP, a cofactor critical for both responses. Accordingly, when one is more active, the other has reduced access to CBP, limiting its ability to induce transcription [<xref rid="bib113" ref-type="bibr">113</xref>]. By enhancing the expression of antioxidant genes and affecting inflammatory processes, NRF2 mitigates inflammation, at least in part through HO-1 induction. HO-1 catabolizes heme into carbon monoxide, iron, and biliverdin, which is then converted into bilirubin. The NRF2&#x02013;HO-1 axis can also downregulate the expression of matrix metalloproteinases, either directly or through NF-&#x003ba;B inhibition [<xref rid="bib114" ref-type="bibr">114</xref>,<xref rid="bib115" ref-type="bibr">115</xref>]. Under sustained oxidative stress with high levels of ROS, NF-&#x003ba;B can induce additional cytokines and proinflammatory responses, triggering a vicious cycle that exacerbates oxidative stress, inflammation, and cellular damage, which in turn contributes to the impairment of NRF2 activity.</p></sec><sec id="sec6"><label>6</label><title>NRF2 and ASD</title><p id="p0135">The activation of NRF2 by ROS represents a critical adaptive mechanism where low-to-moderate ROS levels stimulate antioxidant defenses, while excessive ROS cause cellular damage [<xref rid="bib116" ref-type="bibr">116</xref>]. This biphasic response appears impaired in ASD. Indeed, a growing number of clinical and experimental studies indicate significant alterations in NRF2 signaling, suggesting that its dysfunction may contribute to ASD pathophysiology by increasing oxidative stress, inflammation, and metabolic disturbances (<xref rid="tbl2" ref-type="table">Table 2</xref>).<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Summary of main findings on NRF2 in autism spectrum disorder.</p></caption><alt-text id="alttext0025">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Study model</th><th>Sample type</th><th>NRF2 status</th><th>Key findings</th><th>Study</th></tr></thead><tbody><tr><td align="left">ASD children</td><td align="left">Blood</td><td align="left">NRF2 Polymorphism (rs35652124)</td><td align="left">&#x02191; pNRF2 with DMF</td><td align="left">[<xref rid="bib118" ref-type="bibr">118</xref>]</td></tr><tr><td align="left">ASD children</td><td align="left">Granulocytes</td><td align="left">&#x02193; NRF2 expression</td><td align="left">Impaired redox balance, immunity, and mitochondrial function</td><td align="left">[<xref rid="bib119" ref-type="bibr">119</xref>]</td></tr><tr><td align="left">ASD children</td><td align="left">Blood (plasma)</td><td align="left">&#x02193; NRF2 and KEAP1</td><td align="left">&#x02193; GSH, GR, GPX3, GSH/GSSG; &#x02191; GSSG</td><td align="left">[<xref rid="bib120" ref-type="bibr">120</xref>]</td></tr><tr><td align="left">ASD children</td><td align="left">Blood</td><td align="left">&#x02193; NRF2, &#x02191; KEAP1, &#x02193; GSK-3&#x003b2;</td><td align="left">Impaired antioxidant pathway with dysregulated KEAP1-GSK-3&#x003b2;</td><td align="left">[<xref rid="bib121" ref-type="bibr">121</xref>]</td></tr><tr><td align="left">ASD children</td><td align="left">Neutrophils</td><td align="left">&#x02193; NRF2 response to DEHP</td><td align="left">Impaired NRF2/HO-1 induction by DEHP</td><td align="left">[<xref rid="bib126" ref-type="bibr">126</xref>]</td></tr><tr><td align="left">ASD individuals</td><td align="left">Frontal cortex</td><td align="left">&#x02193; NRF2 expression</td><td align="left">Linked to thiol and cobalamin metabolism disruption</td><td align="left">[<xref rid="bib127" ref-type="bibr">127</xref>]</td></tr><tr><td align="left">ASD children</td><td align="left">Monocytes</td><td align="left">&#x02193; NRF2 expression</td><td align="left">&#x02191; NF-&#x003ba;B, IL-6, IL-1&#x003b2;, nitrotyrosine</td><td align="left">[<xref rid="bib133" ref-type="bibr">133</xref>]</td></tr><tr><td align="left">BTBR mice</td><td align="left">Hippocampus</td><td align="left">&#x02193; NRF2 in males only</td><td align="left">&#x02191; Oxidative stress markers and NOX2, &#x02193; SOD and GSH in males</td><td align="left">[<xref rid="bib138" ref-type="bibr">138</xref>]</td></tr><tr><td align="left">Shank3 KO mice</td><td align="left">Cortex, SH-SY5Y cells</td><td align="left">&#x02193; NRF2 with Trx1 inhibition</td><td align="left">&#x02193; NRF2 and antioxidant genes (NQO1, HO-1)</td><td align="left">[<xref rid="bib20" ref-type="bibr">20</xref>]</td></tr><tr><td align="left">Shank3 KO mice</td><td align="left">Hippocampus</td><td align="left">&#x02193; NRF2 phosphorylation and nuclear translocation</td><td align="left">&#x02191; Oxidative stress and inflammation via NRF2 pathway</td><td align="left">[<xref rid="bib139" ref-type="bibr">139</xref>]</td></tr><tr><td align="left">Chlorpyrifos-induced ASD (rat)</td><td align="left">Hippocampus</td><td align="left">&#x02193; NRF2 expression</td><td align="left">&#x02191; Oxidative stress, &#x02191; NF-&#x003ba;B,in astrocyte</td><td align="left">[<xref rid="bib140" ref-type="bibr">140</xref>]</td></tr><tr><td align="left">NRF2-KO mice exposed to VPA</td><td align="left">Brain</td><td align="left">Absent</td><td align="left">Increased susceptibility to behavioral and oxidative stress effects of VPA</td><td align="left">[<xref rid="bib141" ref-type="bibr">141</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: Autism Spectrum Disorder, ASD; Nuclear factor erythroid 2&#x02013;related factor 2, NRF2; Dimethyl fumarate, DMF; Kelch like ECH-associated protein 1, KEAP1; Reduced glutathione, GSH; Glutathione reductase, GR; Glutathione peroxidase 3, GPX3; Oxidized glutathione, GSSG; Glycogen synthase kinase 3 beta, GSK-3&#x003b2;; Di(2-ethylhexyl) phthalate, DEHP; Heme oxygenase 1, HO-1; Nuclear factor kB, NF-&#x003ba;B; Interleukin 6, IL-6; Interleukin 1 beta, IL-1&#x003b2;; NADPH oxidase 2, NOX2; Superoxide dismutase, SOD; Glutathione, GSH; Thioredoxin 1, Trx1, NADPH quinone oxidoreductase 1, NQO1; Valproic acid, VPA.</p></fn></table-wrap-foot></table-wrap></p><p id="p0140">As mentioned, the genetic architecture of ASD is complex, involving both rare and common variants that contribute to individual risk. The <italic>NFE2L2</italic> gene, encoding NRF2, is located on human chromosome 2 and exhibits substantial genetic variation, with 583 documented allelic forms, including 18 SNPs linked to disease risk [<xref rid="bib117" ref-type="bibr">117</xref>]. NRF2 polymorphisms have been identified as part of the broader genetic landscape of ASD, influencing adaptive responses to oxidative and genotoxic stress. The <italic>NFE2L2</italic> rs35652124 polymorphism, selected for its high minor allele frequency (&#x02265;15&#x000a0;%), affects NRF2 expression. In a cohort of 179 ASD children, those with the CC genotype exhibited higher levels of phosphorylated NRF2 (pNRF2), an active form of the protein that induces antioxidant genes, in response to dimethyl fumarate (DMF), a pharmacological NRF2 inducer, compared to those with T+ genotypes, indicating that this genetic variation influences NRF2 pathway activation by pharmacological agents. Additionally, the CC genotype was associated with increased DNA damage, demonstrated by elevated H2AX levels, but lower plasma 8-oxodG levels, which may reflect differences in DNA repair mechanisms. Consistent with these findings, CC carriers also exhibited a higher cfDNA-to-nuclease activity ratio, suggesting impaired clearance of damaged DNA. Moreover, a correlation between adaptive genotoxic responses, assessed through H2AX, and NRF2-mediated cytoprotection was observed in T+ carriers but not in CC carriers, indicating a disruption in oxidative stress responses in individuals with the CC genotype. These findings suggest that the <italic>NFE2L2</italic> rs35652124 polymorphism modulates oxidative stress responses in children with ASD, affecting their susceptibility to oxidative damage and pharmacological NRF2 activation [<xref rid="bib118" ref-type="bibr">118</xref>].</p><p id="p0145">In addition to genetic factors, one of the first studies to demonstrate the critical role of NRF2 downregulation in mitochondrial dysfunction and immune anomalies in ASD was conducted in granulocytes from children with ASD. The authors reported a 45&#x000a0;% reduction in NRF2 transcript levels compared to typically developing controls, correlating with systemic oxidative stress and impaired bioenergetics. Reduced NRF2 compromised cellular antioxidant defenses, leading to increased mitochondrial ROS production. Likewise, elevated mtDNA deletions indicated persistent oxidative damage. Furthermore, mitochondrial oxidative phosphorylation capacity in ASD granulocytes was reduced, with deficits across multiple electron transport chain complexes [<xref rid="bib119" ref-type="bibr">119</xref>].</p><p id="p0150">A recent pilot study further supports the involvement of oxidative stress in ASD by examining the relationship between NRF2 signaling and glutathione homeostasis in young children. The study reported reduced levels of NRF2 and KEAP1 in children with ASD compared to neurotypical controls, along with lower concentrations of GSH, GR, GPX3, and a decreased GSH/GSSG ratio. These alterations were accompanied by elevated levels of GSSG, indicating increased oxidative stress. Notably, a positive correlation was observed between NRF2, GSH, and GR levels, highlighting the role of NRF2 in regulating antioxidant defenses and maintaining redox balance in ASD [<xref rid="bib120" ref-type="bibr">120</xref>]. A case-control study investigated NRF2, KEAP1, and GSK-3&#x003b2; expression in children with ASD compared to neurotypical controls. NRF2 levels were lower in the ASD group, suggesting an impaired antioxidant response in these children. Conversely, KEAP1 was significantly elevated, contributing to reduced NRF2 availability. Interestingly, GSK-3&#x003b2; expression was found to be lower in the ASD group [<xref rid="bib121" ref-type="bibr">121</xref>]. Given that GSK-3&#x003b2; typically inhibits NRF2 via proteasomal degradation, its reduction did not correspond to the expected NRF2 increase, suggesting broader pathway dysregulation. However, it is important to note that findings on GSK-3&#x003b2; in ASD are heterogeneous. While some studies report reduced GSK-3&#x003b2; expression, others have shown increased GSK-3&#x003b2; activity, potentially contributing to oxidative stress, inflammation, and altered neurodevelopment. These discrepancies may reflect differences in brain regions, developmental stages, or ASD subtypes. These findings highlight the complexity of GSK-3&#x003b2; regulation in ASD and its intricate relationship with NRF2 signaling [<xref rid="bib122" ref-type="bibr">122</xref>,<xref rid="bib123" ref-type="bibr">123</xref>].</p><p id="p0155">As indicated above, extensive evidence suggests that exposure to environmental toxicants, including prenatal in utero exposure, contributes to ASD development [<xref rid="bib124" ref-type="bibr">124</xref>,<xref rid="bib125" ref-type="bibr">125</xref>]. Neutrophils from children with ASD show a dysregulated NRF2 response to di(2-ethylhexyl) phthalate (DEHP) exposure, a class of phthalates used as plasticizers, with an impaired ability to upregulate <italic>HO-1</italic>, a crucial NRF2 target gene involved in mitigating oxidative stress. Conversely, neutrophils from neurotypical children exhibit a robust NRF2/HO-1 response to oxidative insults, such as DEHP exposure, whereas neutrophils from children with ASD have a reduced antioxidant response, suggesting a compromised antioxidant defense mechanism in ASD [<xref rid="bib126" ref-type="bibr">126</xref>].</p><p id="p0160">Decreased NRF2 expression has been reported in the frontal cortex of individuals with ASD, accompanied by disturbances in thiol and cobalamin (vitamin B12) metabolism, both critical for cellular redox balance [<xref rid="bib127" ref-type="bibr">127</xref>]. Cobalamin plays a crucial role in the development, differentiation, and function of the CNS and participates in the methionine-homocysteine metabolic pathway [<xref rid="bib128" ref-type="bibr">128</xref>]. Blood vitamin B12 levels in children with ASD are often lower compared to neurotypical children, leading to impaired homocysteine (HCY) remethylation, elevated HCY concentrations, and DNA hypomethylation, potentially disrupting CNS development [<xref rid="bib16" ref-type="bibr">16</xref>,<xref rid="bib129" ref-type="bibr">129</xref>,<xref rid="bib130" ref-type="bibr">130</xref>]. Moreover, reduced methylcobalamin (MeCbl) and GSH levels correlate with lower NRF2 expression, highlighting the relationship between oxidative stress, metabolic dysfunction, and NRF2 dysregulation in ASD. Notably, decreased NRF2 expression in the frontal cortex of individuals with ASD disrupts cobalamin-dependent sulfur metabolism, resulting in reduced methionine and S-adenosylmethionine (SAM) levels, alongside elevated HCY, indicative of compromised methylation capacity and impaired transsulfuration pathway activity [<xref rid="bib127" ref-type="bibr">127</xref>]. This interdependence between NRF2-mediated antioxidant responses and cobalamin status may drive metabolic disturbances that exacerbate oxidative stress, contributing to neuropathological processes in ASD.</p><p id="p0165">In addition to its role in maintaining redox balance, NRF2 plays a crucial role in regulating inflammation, which can impair normal brain developmental processes such as neuronal migration, differentiation, and synaptogenesis, leading to alterations in brain connectivity and function that contribute to ASD symptoms [<xref rid="bib131" ref-type="bibr">131</xref>,<xref rid="bib132" ref-type="bibr">132</xref>]. Monocytes from children with ASD exhibit decreased NRF2 expression and ARE-binding activity compared to those from neurotypical children, as well as increased inflammatory markers, including NF-&#x003ba;B, interleukin-6 (IL-6), IL-1&#x003b2;, and nitrosative stress markers such as nitrotyrosine [<xref rid="bib133" ref-type="bibr">133</xref>]. These findings suggest that persistent oxidative and nitrosative stress in monocytes from children with ASD may contribute to NRF2 pathway exhaustion through mechanisms such as negative feedback (e.g., increased degradation or suppression of NRF2), post-translational modifications impairing NRF2 stability or function, and potential epigenetic silencing of the NRF2 gene, leading to impaired antioxidant responses and increased susceptibility to inflammatory damage.</p><p id="p0170">Nitrosative stress, caused by RNS, such as NO and peroxynitrite, can activate the NRF2 signaling pathway. This activation is considered a key cellular response to reduce NO-induced apoptosis and support cell survival. Nitrosative stress activates the NRF2 pathway through oxidation-induced intermolecular disulfide bond formation between KEAP1 molecules, particularly involving Cys151, which alters KEAP1 conformation, inhibits NRF2 ubiquitination, and promotes NRF2 stabilization and nuclear translocation [<xref rid="bib134" ref-type="bibr">134</xref>]. Moreover, although direct inhibition of the GSK-3/&#x003b2;-TrCP axis by nitrosative stress is not fully established, nitrosative stress can activate upstream signaling pathways (e.g., PI3K/Akt) that inhibit GSK-3, thereby preventing NRF2 degradation and enhancing its stability. Additionally, reactive nitrogen species, such as peroxynitrite, stimulate PI3K/Akt signaling, with Akt phosphorylation promoting NRF2 accumulation by disrupting KEAP1-NRF2 binding [<xref rid="bib135" ref-type="bibr">135</xref>,<xref rid="bib136" ref-type="bibr">136</xref>]. Impaired NRF2 function has been observed in several major psychiatric and neurodevelopmental disorders, including depression and ASD, leading to increased nitrosative stress that contributes to the pathophysiology of these conditions [<xref rid="bib23" ref-type="bibr">23</xref>].</p><p id="p0175">ASD is diagnosed more frequently in males than females, with differences in neurobiological and behavioral features [<xref rid="bib137" ref-type="bibr">137</xref>]. In a study conducted using the BTBR mouse model of idiopathic autism, male mice exhibited increased repetitive behaviors accompanied by elevated oxidative stress in the hippocampus, as indicated by higher levels of ROS, enhanced expression of pro-oxidant enzymes such as NOX2, and reduced antioxidant defenses characterized by decreased levels of SOD and GSH. These changes were associated with a significant reduction in NRF2 expression, without corresponding alterations in KEAP1 expression, suggesting impaired activation rather than increased degradation of NRF2. Conversely, female BTBR mice showed distinct oxidative stress profiles characterized by increased MDA and elevated <italic>NOX1</italic> expression but maintained an overall more effective antioxidant response without alterations in NRF2 levels [<xref rid="bib138" ref-type="bibr">138</xref>]. Additionally, mice with <italic>Shank3</italic> mutations, which are used to mimic behaviors similar to those seen in humans with ASD, show a reduction in Trx activity, leading to decreased NRF2 expression and increased oxidative and nitrosative stress. Shank3, a synaptic scaffolding protein, plays a critical role in synapse formation, maturation, and maintenance. Its loss reduces the upregulation of key NRF2-target antioxidant genes, including <italic>NQO1</italic> and <italic>HO-1</italic>, increasing neuronal vulnerability to oxidative damage [<xref rid="bib20" ref-type="bibr">20</xref>,<xref rid="bib139" ref-type="bibr">139</xref>]. Other studies using experimental models of ASD have further highlighted the roles of NRF2 and NF-&#x003ba;B as critical components in regulating oxidative stress and neuroinflammation associated with ASD pathology. Chlorpyrifos, an organophosphate pesticide, has been implicated in neurotoxicity, oxidative stress, and neuroinflammation, particularly during early neurodevelopment. In a chlorpyrifos-induced ASD model, excessive glutamate triggered ROS generation, leading to reduced NRF2 expression and increased NF-&#x003ba;B activation, which in turn promoted astrocyte-mediated neuroinflammation and behavioral deficits [<xref rid="bib140" ref-type="bibr">140</xref>]. Likewise, postnatal exposure to valproic acid (VPA), a widely used anticonvulsant to model ASD-like behaviors in rodents, provided evidence that NRF2-deficient mice are more sensitive to the damaging effects of VPA, showing reduced locomotor activity, deficits in motor coordination, and impaired learning and memory [<xref rid="bib141" ref-type="bibr">141</xref>].</p><p id="p0180">Overall, these findings highlight a critical role for NRF2 in ASD, with dysregulation occurring at multiple levels, including genetic, metabolic, inflammatory, and environmental factors. In the next section, we provide an overview of how NRF2 dysfunction may be targeted through pharmacological or dietary interventions to improve the oxidative stress response in ASD.</p></sec><sec id="sec7"><label>7</label><title>Antioxidant interventions using NRF2 inducers in ASD</title><p id="p0185">Although ASD is widely recognized as a multifactorial condition, the evidence discussed above demonstrates that its pathophysiology also involves oxidative stress and impaired NRF2 activity. This impairment is influenced not only by tissue- or context-specific factors, but also by genetic polymorphisms, mitochondrial dysfunction, neuroinflammation, environmental exposures, and disruptions in methylation and cobalamin metabolism [<xref rid="bib127" ref-type="bibr">127</xref>,<xref rid="bib142" ref-type="bibr">142</xref>]. Nonetheless, reduced NRF2 activity appears to be observed in certain contexts within ASD. Therefore, NRF2 can be targeted to regulate oxidative stress and enhance its activity. Notably, many NRF2 modulators act through hormetic mechanisms, inducing mild oxidative challenges that trigger adaptive cellular defenses and activate NRF2 target genes [<xref rid="bib143" ref-type="bibr">143</xref>,<xref rid="bib144" ref-type="bibr">144</xref>]. Several promising NRF2 inducers are currently under investigation, including in preclinical and clinical studies on ASD. There are two classes of NRF2 inducers: cysteine-reactive inducers and protein-protein interaction inhibitors (PPI) [<xref rid="bib145" ref-type="bibr">145</xref>]. Recent evidence from systematic reviews indicates that numerous antioxidant compounds, including flavonoids, N-acetylcysteine (NAC) and sulforaphane (SFN), many of which are well-known NRF2 inducers targeting specific cysteine residues on KEAP1, may improve oxidative stress biomarkers, promote the expression of NRF2 target genes, and ameliorate behaviors associated with ASD. However, while SFN and NAC have been evaluated in some clinical trials, most studies have been performed in ASD animal models, and in many cases, direct NRF2 measurement was not included. [<xref rid="bib146" ref-type="bibr">146</xref>,<xref rid="bib147" ref-type="bibr">147</xref>]. Given the limited translational applicability of ASD experimental models [<xref rid="bib148" ref-type="bibr">148</xref>,<xref rid="bib149" ref-type="bibr">149</xref>], we discuss below only antioxidant compounds known as NRF2 inducers that have been tested in clinical trials (<xref rid="tbl3" ref-type="table">Table 3</xref>).<table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Clinical studies in autism spectrum disorder involving NRF2-inducing antioxidant compounds.</p></caption><alt-text id="alttext0030">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Study Design</th><th>Age</th><th>Sample size (Intervention/Control)</th><th>Compound (Dosage/day)</th><th>Duration</th><th>Outcomes</th><th>Results</th><th>Study</th></tr></thead><tbody><tr><td align="left">Randomized, double-blind, placebo-controlled clinical trial</td><td align="left">13&#x02013;27&#x000a0;yrs</td><td align="left">29/15</td><td align="left">SFN (50&#x02013;150&#x000a0;&#x003bc;mol/day)</td><td align="left">18 weeks</td><td align="left">ABC, SRS, CGI-I</td><td align="left">&#x02193; ABC 34&#x000a0;%, &#x02193; SRS 17&#x000a0;%</td><td align="left">[<xref rid="bib153" ref-type="bibr">153</xref>]</td></tr><tr><td align="left">Follow-up case series</td><td align="left">13&#x02013;27&#x000a0;yrs</td><td align="left">Follow-up on 26 participants from Singh et al., 2014 trial</td><td align="left">SFN (50&#x02013;150&#x000a0;&#x003bc;mol/day)</td><td align="left">Follow-up after 2.5&#x02013;4 years</td><td align="left">Behavioral follow-up (unscored)</td><td align="left">Sustained behavioral improvements</td><td align="left">[<xref rid="bib154" ref-type="bibr">154</xref>]</td></tr><tr><td align="left">Randomized, double-blind, placebo-controlled clinical trial</td><td align="left">3&#x02013;27&#x000a0;yrs</td><td align="left">27/30</td><td align="left">SFN (based on BSA)</td><td align="left">15 weeks</td><td align="left">Behavior, metabolomics</td><td align="left">&#x02193; irritability; improved social and gastrointestinal symptoms, redox modulation</td><td align="left">[<xref rid="bib155" ref-type="bibr">155</xref>]</td></tr><tr><td align="left">Ex vivo controlled study</td><td align="left">N/A</td><td align="left">Monocyte samples from ASD children (number not specified)</td><td align="left">SFN (in vitro treatment)</td><td align="left">N/A</td><td align="left">NRF2, cytokines</td><td align="left">&#x02191; NRF2, &#x02193; inflammation</td><td align="left">[<xref rid="bib133" ref-type="bibr">133</xref>]</td></tr><tr><td align="left">Randomized, double-blind, placebo-controlled clinical trial</td><td align="left">4&#x02013;12&#x000a0;yrs</td><td align="left">30/30</td><td align="left">SFN (50&#x000a0;&#x003bc;mol/day &#x02264;45&#x000a0;kg; 100&#x000a0;&#x003bc;mol/day &#x0003e;45&#x000a0;kg)&#x000a0;+&#x000a0;risperidone</td><td align="left">10 weeks</td><td align="left">ABC</td><td align="left">&#x02193; irritability, &#x02193; hyperactivity</td><td align="left">[<xref rid="bib156" ref-type="bibr">156</xref>]</td></tr><tr><td align="left">Open-label clinical trial</td><td align="left">School-aged (age not specified)</td><td align="left">15 (no control)</td><td align="left">SFN (dose not specified)</td><td align="left">12 weeks</td><td align="left">ABC, SRS</td><td align="left">SRS improved by 9.7 points ABC improved by 7.1 points</td><td align="left">[<xref rid="bib157" ref-type="bibr">157</xref>]</td></tr><tr><td align="left">Randomized, double-blind, placebo-controlled, multicenter trial</td><td align="left">3&#x02013;15&#x000a0;yrs</td><td align="left">54/54</td><td align="left">SFN (dose not specified)</td><td align="left">12 weeks</td><td align="left">ADOS, SRS, CGI</td><td align="left">Significant improvement on clinician-rated scales; not on caregiver</td><td align="left">[<xref rid="bib158" ref-type="bibr">158</xref>]</td></tr><tr><td align="left">Randomized, double-blind, placebo-controlled study</td><td align="left">3&#x02013;7&#x000a0;yrs</td><td align="left">20/20</td><td align="left">SFN (dose not specified)</td><td align="left">36 weeks</td><td align="left">ADOS-2, SRS-2, ABC</td><td align="left">No significant differences between groups on any measures</td><td align="left">[<xref rid="bib159" ref-type="bibr">159</xref>]</td></tr><tr><td align="left">Randomized, double-blind, placebo controlled trial</td><td align="left">3.1&#x02013;9.9&#x000a0;yrs</td><td align="left">51/51</td><td align="left">NAC (500&#x000a0;mg/day)</td><td align="left">6 months</td><td align="left">SRS, CCC-2, RBS-R Vineland, SCQ, ADOS</td><td align="left">No differences between treatment and placebo groups</td><td align="left">[<xref rid="bib163" ref-type="bibr">163</xref>]</td></tr><tr><td align="left">Randomized, double-blind, placebo controlled trial</td><td align="left">4&#x02013;12&#x000a0;yrs</td><td align="left">16/15</td><td align="left">NAC (up to 60&#x000a0;mg/kg/day; max 4200&#x000a0;mg)</td><td/><td align="left">CGI-I, ABC, SRS, VABS-II, oxidative stress markers</td><td align="left">No differences in CGI-I, ABC, SRS, or VABS-II between groups; GSH &#x02191; in NAC group</td><td align="left">[<xref rid="bib164" ref-type="bibr">164</xref>]</td></tr><tr><td align="left">Double-blind, randomized, placebo-controlled pilot trial</td><td align="left">3.2&#x02013;10.7&#x000a0;yrs</td><td align="left">14/15</td><td align="left">NAC 900&#x000a0;mg/day &#x02192; 1800&#x000a0;mg/day &#x02192; 2700&#x000a0;mg/day</td><td align="left">12 weeks</td><td align="left">ABC, SRS, RBS-R</td><td align="left">Significant improvement in irritability</td><td align="left">[<xref rid="bib165" ref-type="bibr">165</xref>]</td></tr><tr><td align="left">Double-blind, placebo-controlled randomized crossover pilot study</td><td align="left">5&#x02013;16&#x000a0;yrs</td><td align="left">24</td><td align="left">Glutathione or Glutathione&#x000a0;+&#x000a0;Vitamin C&#x000a0;+&#x000a0;NAC (weekly)</td><td align="left">8 weeks per phase (2x) +1 week wash out</td><td align="left">Behavioral measures, plasma glutathione levels</td><td align="left">No significant improvements, mild positive trends across all groups</td><td align="left">[<xref rid="bib166" ref-type="bibr">166</xref>]</td></tr><tr><td align="left">Randomized, double-blind, placebo-controlled clinical trial</td><td align="left">Children and adolescents (age not specified)</td><td align="left">20/20</td><td align="left">NAC (1200&#x000a0;mg/day)&#x000a0;+&#x000a0;risperidone</td><td align="left">8 weeks</td><td align="left">ABC Irritability subscale</td><td align="left">Significant reduction in irritability with NAC&#x000a0;+&#x000a0;risperidone</td><td align="left">[<xref rid="bib167" ref-type="bibr">167</xref>]</td></tr><tr><td align="left">Randomized, double-blind, placebo-controlled clinical trial</td><td align="left">4&#x02013;12&#x000a0;yrs</td><td align="left">20/20</td><td align="left">NAC (600&#x02013;900&#x000a0;mg/day) risperidone (1&#x02013;2&#x000a0;mg/day)</td><td align="left">10 weeks</td><td align="left">ABC-C</td><td align="left">Significant reduction in irritability and hyperactivity</td><td align="left">[<xref rid="bib168" ref-type="bibr">168</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: Sulforaphane, SFN; Aberrant behavior checklist, ABC; Social responsiveness scale, SRS; Clinical global impressions &#x02013; improvement scale, CGI-I; Body surface area, BSA; Not Applicable, N/A; Nuclear factor erythroid 2&#x02013;related factor 2, NRF2; Autism diagnostic observation schedule, ADOS; Autism diagnostic observation schedule, second edition, ADOS-2; N-acetyl cysteine, NAC; Children's communication checklist &#x02013; second edition, CCC-2; RBS-R: Repetitive behavior scale &#x02013; revised, RBS-R; Social communication questionnaire, SCQ; Vineland adaptive behavior scales, second edition, VABS-II; Glutathione, GSH; Aberrant behavior checklist &#x02013; community, ABC-C.</p></fn></table-wrap-foot></table-wrap></p><p id="p0190">Currently, one of the most promising clinical candidates for ASD is SFN, a naturally occurring isothiocyanate found in cruciferous vegetables and known for its ability to modulate oxidative stress and inflammation. SFN is highly reactive due to the electrophilic nature of its isothiocyanate group, which activates NRF2 by modifying KEAP1 Cys151, increases the synthesis of GSH, and enhances the expression of NRF2-target genes such as <italic>NQO1</italic>, Trx, <italic>TXNRD1</italic>, <italic>GPX2</italic>, among others [<xref rid="bib150" ref-type="bibr">[150]</xref>, <xref rid="bib151" ref-type="bibr">[151]</xref>, <xref rid="bib152" ref-type="bibr">[152]</xref>].</p><p id="p0195">In a seminal randomized, placebo-controlled clinical trial, young individuals with ASD have been administered daily doses of SFN-rich broccoli sprout extract for 18 weeks, showing significant improvements across several behavioral dimensions, including decreased irritability, hyperactivity, stereotypical behaviors, and enhanced social responsiveness [<xref rid="bib153" ref-type="bibr">153</xref>]. Moreover, findings from a follow-up case series with the same cohort suggest that SFN had beneficial effects during the subsequent three-year follow-up period [<xref rid="bib154" ref-type="bibr">154</xref>]. However, the same research group, unable to use the previous SFN-rich preparations in a new cohort, reported that SFN led to small but non-statistically significant changes in the clinical outcomes of 45 children with ASD [<xref rid="bib155" ref-type="bibr">155</xref>]. In monocytes from children with ASD, NRF2 expression and activity are initially impaired, which is linked to increased inflammation and nitrosative stress. However, SFN treatment activates NRF2 by enhancing its nuclear translocation and DNA-binding activity to AREs. This activation counteracts oxidative/nitrosative stress and inflammation by downregulating NF&#x003ba;B signaling and reducing pro-inflammatory cytokines and stress marker [<xref rid="bib133" ref-type="bibr">133</xref>].</p><p id="p0200">Another clinical study assessed SFN supplementation in combination with risperidone, an antipsychotic demonstrating significant improvements in irritability and hyperactivity scores, as well as a trend toward improvement in stereotypic behaviors in children with ASD [<xref rid="bib156" ref-type="bibr">156</xref>]. In an open-label study of children with ASD treated with SFN, improvements in social responsiveness have been reported. Urinary metabolomics analysis identified 77 metabolites correlated with symptom changes, clustering into pathways related to oxidative stress, among various other metabolic processes [<xref rid="bib157" ref-type="bibr">157</xref>]. Interestingly, the largest randomized, double-blind, placebo-controlled trial of SFN for ASD treatment to date, which enrolled 108 children, reported mixed results. While caregiver-rated scales showed no significant difference between the SFN and placebo groups, clinician-rated scales indicated significant improvements with SFN treatment [<xref rid="bib158" ref-type="bibr">158</xref>]. In another pediatric cohort of ASD patients, no significant clinical improvement has been observed in behavioral outcomes following a 36-week SFN treatment [<xref rid="bib159" ref-type="bibr">159</xref>]. Overall, despite compelling experimental evidence that SFN modulates NRF2, its clinical efficacy in ASD remains inconsistently supported across trials.</p><p id="p0205">NAC, a mucolytic agent approved by the FDA, is a well-known antioxidant compound that increases GSH levels, protecting against oxidative damage. As an inducer of NRF2 activity, the thiol group of NAC may interact with cysteine residues on KEAP1, leading to NRF2 translocation to the nucleus and activation of ARE-driven genes [<xref rid="bib160" ref-type="bibr">[160]</xref>, <xref rid="bib161" ref-type="bibr">[161]</xref>, <xref rid="bib162" ref-type="bibr">[162]</xref>]. The effect of NAC on reducing abnormal behaviors in ASD has been evaluated in some clinical trials. One large placebo-controlled trial involving 102 participants found no significant improvements in social responsiveness, communication, or repetitive behaviors with NAC treatment [<xref rid="bib163" ref-type="bibr">163</xref>]. Another 12-week randomized study assessing NAC for core social impairment in ASD also reported no significant clinical effects, despite confirming an increase in GSH levels [<xref rid="bib164" ref-type="bibr">164</xref>]. However, a pilot study found that NAC led to significant reductions in irritability [<xref rid="bib165" ref-type="bibr">165</xref>]. Likewise, a recent trial investigating glutathione, alone or in combination with NAC and vitamin C, found no significant behavioral or biological improvements in children with ASD, further demonstrating the limited clinical utility of NAC and other antioxidant interventions in improving ASD-related behavioral symptoms [<xref rid="bib166" ref-type="bibr">166</xref>]. However, two randomized, double-blind, placebo-controlled studies demonstrated that adding NAC to risperidone led to significantly greater reductions in irritability and hyperactivity compared to risperidone alone. At the same time, NAC had no impact on core ASD symptoms beyond reducing irritability. These findings suggest that NAC may enhance the therapeutic effects of risperidone in managing behavioral symptoms associated with ASD [<xref rid="bib167" ref-type="bibr">167</xref>,<xref rid="bib168" ref-type="bibr">168</xref>].</p><p id="p0210">A meta-analysis further evaluated the efficacy of antioxidant interventions in managing ASD symptoms by analyzing 13 double-blind, randomized clinical trials involving a total of 570 patients with ASD. The analysis assessed eight antioxidant compounds, many of which are well-known NRF2 inducers, including NAC, resveratrol, SFN, folic acid, coenzyme Q10, vitamin C, vitamin D, and omega-3 fatty acids. Although effect sizes were small, the findings indicate that antioxidants improved irritability and communication disturbances, with promising trends for stereotypic behavior and hyperactivity symptoms, suggesting that these interventions may play a role in managing certain symptoms in patients with ASD [<xref rid="bib146" ref-type="bibr">146</xref>].</p></sec><sec id="sec8"><label>8</label><title>Conclusions</title><p id="p0215">Although our understanding of its causes has improved, ASD remains one of the most complex neurodevelopmental disorders, with a combination of genetic, neurobiological, and environmental factors that is not yet fully understood, contributing to its complex phenotype.</p><p id="p0220">The lack of established biomarkers and pharmacological treatments for ASD is mainly due to the clinical and biological diversity of the condition, as well as persistent challenges in biomarker validation and treatment development. The wide variation in genetic, metabolic, and neuroinflammatory profiles among individuals with ASD complicates the identification of reliable and reproducible biomarkers.</p><p id="p0225">Among the various biochemical and metabolic alterations occurring at both systemic and brain levels, we have discussed how oxidative stress and its associated biomarkers may contribute to the pathophysiology of ASD. Multiple biomarkers of oxidative stress, including elevated lipid peroxides, protein and DNA oxidation products, and deficiencies in antioxidant enzyme activities, have been consistently reported in individuals with ASD. These alterations may be linked to an impaired endogenous antioxidant response, mainly regulated by the transcriptional activity of NRF2, whose role in ASD has been increasingly recognized and reported to be dysregulated in experimental and clinical studies. Accordingly, pharmacological and dietary strategies using antioxidant compounds, such as SFN and NAC, which are known to induce NRF2, represent a rational approach to restoring its activity in ASD. However, despite some promising results, current evidence remains inconclusive about their clinical efficacy. Moreover, the majority of clinical trials conducted so far have only focused on measuring behavioral outcomes. Future studies evaluating antioxidant interventions in ASD should include measurements of oxidative stress biomarkers, direct assessments of NRF2 activity, and examination of how these interventions influence NRF2-target genes in ASD populations.</p></sec><sec id="sec9"><title>CRediT authorship contribution statement</title><p id="p0230"><bold>Sergio Davinelli:</bold> Writing &#x02013; review &#x00026; editing, Writing &#x02013; original draft, Investigation, Data curation, Conceptualization. <bold>Alessandro Medoro:</bold> Writing &#x02013; original draft, Visualization, Resources, Formal analysis. <bold>Martina Siracusano:</bold> Conceptualization. <bold>Rosa Savino:</bold> Writing &#x02013; original draft, Conceptualization. <bold>Luciano Saso:</bold> Writing &#x02013; review &#x00026; editing, Conceptualization. <bold>Giovanni Scapagnini:</bold> Writing &#x02013; review &#x00026; editing, Supervision, Conceptualization. <bold>Luigi Mazzone:</bold> Writing &#x02013; review &#x00026; editing, Supervision, Conceptualization.</p></sec><sec id="sec10"><title>Ethical approval</title><p id="p0235">Not applicable.</p></sec><sec id="sec11"><title>Funding</title><p id="p0240">No source of funding is associated with this article.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of competing interest</title><p id="p0245">The authors whose names are listed immediately below certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers&#x02019; bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><collab>Global Burden of Disease Study 2021</collab></person-group><article-title>Autism Spectrum Collaborators, the global epidemiology and health burden of the autism spectrum: findings from the Global Burden of Disease Study 2021</article-title><source>Lancet Psychiatry</source><year>2024</year><pub-id pub-id-type="doi">10.1016/S2215-0366(24)00363-8</pub-id><comment>S2215-0366(24)00363&#x02013;8</comment></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>H.</given-names></name><name><surname>Liang</surname><given-names>Z.</given-names></name><name><surname>Ma</surname><given-names>G.</given-names></name><name><surname>Qureshi</surname><given-names>A.</given-names></name><name><surname>Ran</surname><given-names>X.</given-names></name><name><surname>Feng</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name></person-group><article-title>Autism spectrum disorder: pathogenesis, biomarker, and intervention therapy</article-title><source>MedComm</source><volume>5</volume><year>2024</year><object-id pub-id-type="publisher-id">e497</object-id><pub-id pub-id-type="doi">10.1002/mco2.497</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Qiu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name></person-group><article-title>Recent research progress in autism spectrum disorder</article-title><source>Neurosci. Bull.</source><volume>33</volume><year>2017</year><fpage>125</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1007/s12264-017-0117-2</pub-id><pub-id pub-id-type="pmid">28285467</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>M.</given-names></name><name><surname>Lu</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Autism spectrum disorder research: knowledge mapping of progress and focus between 2011 and 2022</article-title><source>Front. Psychiatr.</source><volume>14</volume><year>2023</year><object-id pub-id-type="publisher-id">1096769</object-id><pub-id pub-id-type="doi">10.3389/fpsyt.2023.1096769</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Asif</surname><given-names>M.</given-names></name><name><surname>Martiniano</surname><given-names>H.F.M.C.</given-names></name><name><surname>Marques</surname><given-names>A.R.</given-names></name><name><surname>Santos</surname><given-names>J.X.</given-names></name><name><surname>Vilela</surname><given-names>J.</given-names></name><name><surname>Rasga</surname><given-names>C.</given-names></name><name><surname>Oliveira</surname><given-names>G.</given-names></name><name><surname>Couto</surname><given-names>F.M.</given-names></name><name><surname>Vicente</surname><given-names>A.M.</given-names></name></person-group><article-title>Identification of biological mechanisms underlying a multidimensional ASD phenotype using machine learning</article-title><source>Transl. Psychiatry</source><volume>10</volume><year>2020</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41398-020-0721-1</pub-id><pub-id pub-id-type="pmid">32066695</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Abedini</surname><given-names>S.S.</given-names></name><name><surname>Akhavantabasi</surname><given-names>S.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Heng</surname><given-names>J.I.-T.</given-names></name><name><surname>Alizadehsani</surname><given-names>R.</given-names></name><name><surname>Dehzangi</surname><given-names>I.</given-names></name><name><surname>Bauer</surname><given-names>D.C.</given-names></name><name><surname>Alinejad-Rokny</surname><given-names>H.</given-names></name></person-group><article-title>A critical review of the impact of candidate copy number variants on autism spectrum disorder</article-title><source>Mutat. Res. Rev. Mutat. Res.</source><volume>794</volume><year>2024</year><object-id pub-id-type="publisher-id">108509</object-id><pub-id pub-id-type="doi">10.1016/j.mrrev.2024.108509</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>C.-C.</given-names></name><name><surname>Lin</surname><given-names>L.-S.</given-names></name><name><surname>Long</surname><given-names>S.</given-names></name><name><surname>Ke</surname><given-names>X.-Y.</given-names></name><name><surname>Fukunaga</surname><given-names>K.</given-names></name><name><surname>Lu</surname><given-names>Y.-M.</given-names></name><name><surname>Han</surname><given-names>F.</given-names></name></person-group><article-title>Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications</article-title><source>Signal Transduct. Target. Ther.</source><volume>7</volume><year>2022</year><fpage>1</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/s41392-022-01081-0</pub-id><pub-id pub-id-type="pmid">34980881</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Courchesne</surname><given-names>E.</given-names></name><name><surname>Pramparo</surname><given-names>T.</given-names></name><name><surname>Gazestani</surname><given-names>V.H.</given-names></name><name><surname>Lombardo</surname><given-names>M.V.</given-names></name><name><surname>Pierce</surname><given-names>K.</given-names></name><name><surname>Lewis</surname><given-names>N.E.</given-names></name></person-group><article-title>The ASD Living Biology: from cell proliferation to clinical phenotype</article-title><source>Mol. Psychiatr.</source><volume>24</volume><year>2019</year><fpage>88</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/s41380-018-0056-y</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Love</surname><given-names>C.</given-names></name><name><surname>Sominsky</surname><given-names>L.</given-names></name><name><surname>O'Hely</surname><given-names>M.</given-names></name><name><surname>Berk</surname><given-names>M.</given-names></name><name><surname>Vuillermin</surname><given-names>P.</given-names></name><name><surname>Dawson</surname><given-names>S.L.</given-names></name></person-group><article-title>Prenatal environmental risk factors for autism spectrum disorder and their potential mechanisms</article-title><source>BMC Med.</source><volume>22</volume><year>2024</year><fpage>393</fpage><pub-id pub-id-type="doi">10.1186/s12916-024-03617-3</pub-id><pub-id pub-id-type="pmid">39278907</pub-id>
</element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Lan</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name></person-group><article-title>Prenatal, perinatal and parental risk factors for autism spectrum disorder in China: a case- control study</article-title><source>BMC Psychiatry</source><volume>24</volume><year>2024</year><fpage>219</fpage><pub-id pub-id-type="doi">10.1186/s12888-024-05643-0</pub-id><pub-id pub-id-type="pmid">38509469</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Rossignol</surname><given-names>D.A.</given-names></name><name><surname>Frye</surname><given-names>R.E.</given-names></name></person-group><article-title>A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures</article-title><source>Mol. Psychiatr.</source><volume>17</volume><year>2012</year><fpage>389</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1038/mp.2011.165</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Liang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Zhao</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Gai</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name></person-group><article-title>Correlation of gut microbiome between ASD children and mothers and potential biomarkers for risk assessment</article-title><source>Genom. Proteom. Bioinform.</source><volume>17</volume><year>2019</year><fpage>26</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.gpb.2019.01.002</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Pangrazzi</surname><given-names>L.</given-names></name><name><surname>Balasco</surname><given-names>L.</given-names></name><name><surname>Bozzi</surname><given-names>Y.</given-names></name></person-group><article-title>Oxidative stress and immune system dysfunction in autism spectrum disorders</article-title><source>Int. J. Mol. Sci.</source><volume>21</volume><year>2020</year><fpage>3293</fpage><pub-id pub-id-type="doi">10.3390/ijms21093293</pub-id><pub-id pub-id-type="pmid">32384730</pub-id>
</element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Hirayama</surname><given-names>A.</given-names></name><name><surname>Wakusawa</surname><given-names>K.</given-names></name><name><surname>Fujioka</surname><given-names>T.</given-names></name><name><surname>Iwata</surname><given-names>K.</given-names></name><name><surname>Usui</surname><given-names>N.</given-names></name><name><surname>Kurita</surname><given-names>D.</given-names></name><name><surname>Kameno</surname><given-names>Y.</given-names></name><name><surname>Wakuda</surname><given-names>T.</given-names></name><name><surname>Takagai</surname><given-names>S.</given-names></name><name><surname>Hirai</surname><given-names>T.</given-names></name><name><surname>Nara</surname><given-names>T.</given-names></name><name><surname>Ito</surname><given-names>H.</given-names></name><name><surname>Nagano</surname><given-names>Y.</given-names></name><name><surname>Oowada</surname><given-names>S.</given-names></name><name><surname>Tsujii</surname><given-names>M.</given-names></name><name><surname>Tsuchiya</surname><given-names>K.J.</given-names></name><name><surname>Matsuzaki</surname><given-names>H.</given-names></name></person-group><article-title>Simultaneous evaluation of antioxidative serum profiles facilitates the diagnostic screening of autism spectrum disorder in under-6-year-old children</article-title><source>Sci. Rep.</source><volume>10</volume><year>2020</year><object-id pub-id-type="publisher-id">20602</object-id><pub-id pub-id-type="doi">10.1038/s41598-020-77328-z</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Bj&#x000f8;rklund</surname><given-names>G.</given-names></name><name><surname>Tinkov</surname><given-names>A.A.</given-names></name><name><surname>Hosnedlov&#x000e1;</surname><given-names>B.</given-names></name><name><surname>Kizek</surname><given-names>R.</given-names></name><name><surname>Ajsuvakova</surname><given-names>O.P.</given-names></name><name><surname>Chirumbolo</surname><given-names>S.</given-names></name><name><surname>Skalnaya</surname><given-names>M.G.</given-names></name><name><surname>Peana</surname><given-names>M.</given-names></name><name><surname>Dadar</surname><given-names>M.</given-names></name><name><surname>El-Ansary</surname><given-names>A.</given-names></name><name><surname>Qasem</surname><given-names>H.</given-names></name><name><surname>Adams</surname><given-names>J.B.</given-names></name><name><surname>Aaseth</surname><given-names>J.</given-names></name><name><surname>Skalny</surname><given-names>A.V.</given-names></name></person-group><article-title>The role of glutathione redox imbalance in autism spectrum disorder: a review</article-title><source>Free Radic. Biol. Med.</source><volume>160</volume><year>2020</year><fpage>149</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2020.07.017</pub-id><pub-id pub-id-type="pmid">32745763</pub-id>
</element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>X.-J.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Mao</surname><given-names>X.</given-names></name><name><surname>Gui</surname><given-names>L.-N.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name></person-group><article-title>Oxidative stress marker aberrations in children with autism spectrum disorder: a systematic review and meta-analysis of 87 studies (N = 9109)</article-title><source>Transl. Psychiatry</source><volume>11</volume><year>2021</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/s41398-020-01135-3</pub-id><pub-id pub-id-type="pmid">33414379</pub-id>
</element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>S.</given-names></name><name><surname>Melnyk</surname><given-names>S.</given-names></name><name><surname>Pavliv</surname><given-names>O.</given-names></name><name><surname>Bai</surname><given-names>S.</given-names></name><name><surname>Nick</surname><given-names>T.G.</given-names></name><name><surname>Frye</surname><given-names>R.E.</given-names></name><name><surname>James</surname><given-names>S.J.</given-names></name></person-group><article-title>Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain</article-title><source>Transl. Psychiatry</source><volume>2</volume><year>2012</year><pub-id pub-id-type="doi">10.1038/TP.2012.61</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Altun</surname><given-names>H.</given-names></name><name><surname>&#x0015e;ahin</surname><given-names>N.</given-names></name><name><surname>Kuruta&#x0015f;</surname><given-names>E.B.</given-names></name><name><surname>Karaaslan</surname><given-names>U.</given-names></name><name><surname>Sevgen</surname><given-names>F.H.</given-names></name><name><surname>F&#x00131;nd&#x00131;kl&#x00131;</surname><given-names>E.</given-names></name></person-group><article-title>Assessment of malondialdehyde levels, superoxide dismutase, and catalase activity in children with autism spectrum disorders</article-title><source>Psychiatr. Clin. Psychopharmacol.</source><volume>28</volume><year>2018</year><fpage>408</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1080/24750573.2018.1470360</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Yenkoyan</surname><given-names>K.</given-names></name><name><surname>Harutyunyan</surname><given-names>H.</given-names></name><name><surname>Harutyunyan</surname><given-names>A.</given-names></name></person-group><article-title>A certain role of SOD/CAT imbalance in pathogenesis of autism spectrum disorders</article-title><source>Free Radic. Biol. Med.</source><volume>123</volume><year>2018</year><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2018.05.070</pub-id><pub-id pub-id-type="pmid">29782990</pub-id>
</element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Bazbaz</surname><given-names>W.</given-names></name><name><surname>Kartawy</surname><given-names>M.</given-names></name><name><surname>Hamoudi</surname><given-names>W.</given-names></name><name><surname>Ojha</surname><given-names>S.K.</given-names></name><name><surname>Khaliulin</surname><given-names>I.</given-names></name><name><surname>Amal</surname><given-names>H.</given-names></name></person-group><article-title>The role of thioredoxin system in Shank3 mouse model of autism</article-title><source>J. Mol. Neurosci.</source><volume>74</volume><year>2024</year><fpage>90</fpage><pub-id pub-id-type="doi">10.1007/s12031-024-02270-y</pub-id><pub-id pub-id-type="pmid">39347996</pub-id>
</element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>He</surname><given-names>F.</given-names></name><name><surname>Ru</surname><given-names>X.</given-names></name><name><surname>Wen</surname><given-names>T.</given-names></name></person-group><article-title>NRF2, a transcription factor for stress response and beyond</article-title><source>Int. J. Mol. Sci.</source><volume>21</volume><year>2020</year><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.3390/IJMS21134777</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>D.</given-names></name><name><surname>Portales-Casamar</surname><given-names>E.</given-names></name><name><surname>Singh</surname><given-names>A.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Arenillas</surname><given-names>D.</given-names></name><name><surname>Happel</surname><given-names>C.</given-names></name><name><surname>Shyr</surname><given-names>C.</given-names></name><name><surname>Wakabayashi</surname><given-names>N.</given-names></name><name><surname>Kensler</surname><given-names>T.W.</given-names></name><name><surname>Wasserman</surname><given-names>W.W.</given-names></name><name><surname>Biswal</surname><given-names>S.</given-names></name></person-group><article-title>Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis</article-title><source>Nucleic Acids Res.</source><volume>38</volume><year>2010</year><fpage>5718</fpage><lpage>5734</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq212</pub-id><pub-id pub-id-type="pmid">20460467</pub-id>
</element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>G.</given-names></name><name><surname>Walker</surname><given-names>A.J.</given-names></name><name><surname>Walder</surname><given-names>K.</given-names></name><name><surname>Berk</surname><given-names>M.</given-names></name><name><surname>Marx</surname><given-names>W.</given-names></name><name><surname>Carvalho</surname><given-names>A.F.</given-names></name><name><surname>Maes</surname><given-names>M.</given-names></name><name><surname>Puri</surname><given-names>B.K.</given-names></name></person-group><article-title>Increasing Nrf2 activity as a treatment approach in neuropsychiatry</article-title><source>Mol. Neurobiol.</source><volume>58</volume><year>2021</year><fpage>2158</fpage><lpage>2182</lpage><pub-id pub-id-type="doi">10.1007/s12035-020-02212-w</pub-id><pub-id pub-id-type="pmid">33411248</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Bhandari</surname><given-names>R.</given-names></name><name><surname>Kaur</surname><given-names>J.</given-names></name><name><surname>Kaur</surname><given-names>S.</given-names></name><name><surname>Kuhad</surname><given-names>A.</given-names></name></person-group><article-title>The Nrf2 pathway in psychiatric disorders: pathophysiological role and potential targeting</article-title><source>Expert Opin. Ther. Targets</source><volume>25</volume><year>2021</year><fpage>115</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1080/14728222.2021.1887141</pub-id><pub-id pub-id-type="pmid">33557652</pub-id>
</element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Bj&#x000f8;rklund</surname><given-names>G.</given-names></name><name><surname>Meguid</surname><given-names>N.A.</given-names></name><name><surname>El-Bana</surname><given-names>M.A.</given-names></name><name><surname>Tinkov</surname><given-names>A.A.</given-names></name><name><surname>Saad</surname><given-names>K.</given-names></name><name><surname>Dadar</surname><given-names>M.</given-names></name><name><surname>Hemimi</surname><given-names>M.</given-names></name><name><surname>Skalny</surname><given-names>A.V.</given-names></name><name><surname>Hosnedlov&#x000e1;</surname><given-names>B.</given-names></name><name><surname>Kizek</surname><given-names>R.</given-names></name><name><surname>Osredkar</surname><given-names>J.</given-names></name><name><surname>Urbina</surname><given-names>M.A.</given-names></name><name><surname>Fabjan</surname><given-names>T.</given-names></name><name><surname>El-Houfey</surname><given-names>A.A.</given-names></name><name><surname>Ka&#x00142;u&#x0017c;na-Czapli&#x00144;ska</surname><given-names>J.</given-names></name><name><surname>G&#x00105;tarek</surname><given-names>P.</given-names></name><name><surname>Chirumbolo</surname><given-names>S.</given-names></name></person-group><article-title>Oxidative stress in autism spectrum disorder</article-title><source>Mol. Neurobiol.</source><volume>57</volume><year>2020</year><fpage>2314</fpage><lpage>2332</lpage><pub-id pub-id-type="doi">10.1007/S12035-019-01742-2</pub-id><pub-id pub-id-type="pmid">32026227</pub-id>
</element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Usui</surname><given-names>N.</given-names></name><name><surname>Kobayashi</surname><given-names>H.</given-names></name><name><surname>Shimada</surname><given-names>S.</given-names></name></person-group><article-title>Neuroinflammation and oxidative stress in the pathogenesis of autism spectrum disorder</article-title><source>Int. J. Mol. Sci.</source><volume>24</volume><year>2023</year><pub-id pub-id-type="doi">10.3390/IJMS24065487</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>D.P.</given-names></name><name><surname>Sies</surname><given-names>H.</given-names></name></person-group><article-title>The redox code</article-title><source>Antioxidants Redox Signal.</source><volume>23</volume><year>2015</year><fpage>734</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1089/ars.2015.6247</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Sies</surname><given-names>H.</given-names></name><name><surname>Berndt</surname><given-names>C.</given-names></name><name><surname>Jones</surname><given-names>D.P.</given-names></name></person-group><article-title>Oxidative stress</article-title><source>Annu. Rev. Biochem.</source><volume>86</volume><year>2017</year><fpage>715</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-061516-045037</pub-id><pub-id pub-id-type="pmid">28441057</pub-id>
</element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Sies</surname><given-names>H.</given-names></name><name><surname>Jones</surname><given-names>D.P.</given-names></name></person-group><article-title>Reactive oxygen species (ROS) as pleiotropic physiological signalling agents</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>21</volume><year>2020</year><fpage>363</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1038/S41580-020-0230-3</pub-id><pub-id pub-id-type="pmid">32231263</pub-id>
</element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Bienert</surname><given-names>G.P.</given-names></name><name><surname>Schjoerring</surname><given-names>J.K.</given-names></name><name><surname>Jahn</surname><given-names>T.P.</given-names></name></person-group><article-title>Membrane transport of hydrogen peroxide</article-title><source>Biochim. Biophys. Acta</source><volume>1758</volume><year>2006</year><fpage>994</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2006.02.015</pub-id><pub-id pub-id-type="pmid">16566894</pub-id>
</element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Brewer</surname><given-names>T.F.</given-names></name><name><surname>Garcia</surname><given-names>F.J.</given-names></name><name><surname>Onak</surname><given-names>C.S.</given-names></name><name><surname>Carroll</surname><given-names>K.S.</given-names></name><name><surname>Chang</surname><given-names>C.J.</given-names></name></person-group><article-title>Chemical approaches to discovery and study of sources and targets of hydrogen peroxide redox signaling through NADPH oxidase proteins</article-title><source>Annu. Rev. Biochem.</source><volume>84</volume><year>2015</year><fpage>765</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060614-034018</pub-id><pub-id pub-id-type="pmid">26034893</pub-id>
</element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Sies</surname><given-names>H.</given-names></name></person-group><article-title>Role of metabolic H2O2 generation</article-title><source>J. Biol. Chem.</source><volume>289</volume><year>2014</year><fpage>8735</fpage><lpage>8741</lpage><pub-id pub-id-type="doi">10.1074/jbc.R113.544635</pub-id><pub-id pub-id-type="pmid">24515117</pub-id>
</element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Di Marzo</surname><given-names>N.</given-names></name><name><surname>Chisci</surname><given-names>E.</given-names></name><name><surname>Giovannoni</surname><given-names>R.</given-names></name></person-group><article-title>The role of hydrogen peroxide in redox-dependent signaling: homeostatic and pathological responses in mammalian cells</article-title><source>Cells</source><volume>7</volume><year>2018</year><fpage>156</fpage><pub-id pub-id-type="doi">10.3390/cells7100156</pub-id><pub-id pub-id-type="pmid">30287799</pub-id>
</element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Lismont</surname><given-names>C.</given-names></name><name><surname>Revenco</surname><given-names>I.</given-names></name><name><surname>Fransen</surname><given-names>M.</given-names></name></person-group><article-title>Peroxisomal hydrogen peroxide metabolism and signaling in health and disease</article-title><source>Int. J. Mol. Sci.</source><volume>20</volume><year>2019</year><fpage>3673</fpage><pub-id pub-id-type="doi">10.3390/ijms20153673</pub-id><pub-id pub-id-type="pmid">31357514</pub-id>
</element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>C.</given-names></name><name><surname>Mu&#x000f1;oz-Palma</surname><given-names>E.</given-names></name><name><surname>Gonz&#x000e1;lez-Billault</surname><given-names>C.</given-names></name></person-group><article-title>From birth to death: a role for reactive oxygen species in neuronal development</article-title><source>Semin. Cell Dev. Biol.</source><volume>80</volume><year>2018</year><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2017.09.012</pub-id><pub-id pub-id-type="pmid">28899716</pub-id>
</element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Oswald</surname><given-names>M.C.W.</given-names></name><name><surname>Garnham</surname><given-names>N.</given-names></name><name><surname>Sweeney</surname><given-names>S.T.</given-names></name><name><surname>Landgraf</surname><given-names>M.</given-names></name></person-group><article-title>Regulation of neuronal development and function by ROS</article-title><source>FEBS Lett.</source><volume>592</volume><year>2018</year><fpage>679</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.12972</pub-id><pub-id pub-id-type="pmid">29323696</pub-id>
</element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Ibi</surname><given-names>M.</given-names></name><name><surname>Haga</surname><given-names>R.</given-names></name><name><surname>Iwata</surname><given-names>K.</given-names></name><name><surname>Matsumoto</surname><given-names>M.</given-names></name><name><surname>Asaoka</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Katsuyama</surname><given-names>M.</given-names></name><name><surname>Yabe-Nishimura</surname><given-names>C.</given-names></name></person-group><article-title>NOX1/NADPH oxidase affects the development of autism-like behaviors in a maternal immune activation model</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>534</volume><year>2021</year><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.11.070</pub-id><pub-id pub-id-type="pmid">33310189</pub-id>
</element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Al-Harbi</surname><given-names>N.O.</given-names></name><name><surname>Nadeem</surname><given-names>A.</given-names></name><name><surname>Ahmad</surname><given-names>S.F.</given-names></name><name><surname>Al-Ayadhi</surname><given-names>L.Y.</given-names></name><name><surname>Al-Harbi</surname><given-names>M.M.</given-names></name><name><surname>As Sobeai</surname><given-names>H.M.</given-names></name><name><surname>Ibrahim</surname><given-names>K.E.</given-names></name><name><surname>Bakheet</surname><given-names>S.A.</given-names></name></person-group><article-title>Elevated expression of toll-like receptor 4 is associated with NADPH oxidase-induced oxidative stress in B cells of children with autism</article-title><source>Int. Immunopharmacol.</source><volume>84</volume><year>2020</year><object-id pub-id-type="publisher-id">106555</object-id><pub-id pub-id-type="doi">10.1016/j.intimp.2020.106555</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Dikalov</surname><given-names>S.</given-names></name></person-group><article-title>Crosstalk between mitochondria and NADPH oxidases</article-title><source>Free Radic. Biol. Med.</source><volume>51</volume><year>2011</year><fpage>1289</fpage><lpage>1301</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2011.06.033</pub-id><pub-id pub-id-type="pmid">21777669</pub-id>
</element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Frye</surname><given-names>R.E.</given-names></name><name><surname>Rincon</surname><given-names>N.</given-names></name><name><surname>McCarty</surname><given-names>P.J.</given-names></name><name><surname>Brister</surname><given-names>D.</given-names></name><name><surname>Scheck</surname><given-names>A.C.</given-names></name><name><surname>Rossignol</surname><given-names>D.A.</given-names></name></person-group><article-title>Biomarkers of mitochondrial dysfunction in autism spectrum disorder: a systematic review and meta-analysis</article-title><source>Neurobiol. Dis.</source><volume>197</volume><year>2024</year><object-id pub-id-type="publisher-id">106520</object-id><pub-id pub-id-type="doi">10.1016/j.nbd.2024.106520</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Frye</surname><given-names>R.E.</given-names></name><name><surname>Lionnard</surname><given-names>L.</given-names></name><name><surname>Singh</surname><given-names>I.</given-names></name><name><surname>Karim</surname><given-names>M.A.</given-names></name><name><surname>Chajra</surname><given-names>H.</given-names></name><name><surname>Frechet</surname><given-names>M.</given-names></name><name><surname>Kissa</surname><given-names>K.</given-names></name><name><surname>Racine</surname><given-names>V.</given-names></name><name><surname>Ammanamanchi</surname><given-names>A.</given-names></name><name><surname>McCarty</surname><given-names>P.J.</given-names></name><name><surname>Delhey</surname><given-names>L.</given-names></name><name><surname>Tippett</surname><given-names>M.</given-names></name><name><surname>Rose</surname><given-names>S.</given-names></name><name><surname>Aouacheria</surname><given-names>A.</given-names></name></person-group><article-title>Mitochondrial morphology is associated with respiratory chain uncoupling in autism spectrum disorder</article-title><source>Transl. Psychiatry</source><volume>11</volume><year>2021</year><fpage>527</fpage><pub-id pub-id-type="doi">10.1038/s41398-021-01647-6</pub-id><pub-id pub-id-type="pmid">34645790</pub-id>
</element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Giulivi</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.-F.</given-names></name><name><surname>Omanska-Klusek</surname><given-names>A.</given-names></name><name><surname>Ross-Inta</surname><given-names>C.</given-names></name><name><surname>Wong</surname><given-names>S.</given-names></name><name><surname>Hertz-Picciotto</surname><given-names>I.</given-names></name><name><surname>Tassone</surname><given-names>F.</given-names></name><name><surname>Pessah</surname><given-names>I.N.</given-names></name></person-group><article-title>Mitochondrial dysfunction in autism</article-title><source>JAMA</source><volume>304</volume><year>2010</year><fpage>2389</fpage><lpage>2396</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.1706</pub-id><pub-id pub-id-type="pmid">21119085</pub-id>
</element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>H.</given-names></name><name><surname>Zakaria</surname><given-names>F.</given-names></name><name><surname>Makpol</surname><given-names>S.</given-names></name><name><surname>Karim</surname><given-names>N.A.</given-names></name></person-group><article-title>A link between mitochondrial dysregulation and idiopathic autism spectrum disorder (ASD): alterations in mitochondrial respiratory capacity and membrane potential</article-title><source>Curr. Issues Mol. Biol.</source><volume>43</volume><year>2021</year><fpage>2238</fpage><lpage>2252</lpage><pub-id pub-id-type="doi">10.3390/cimb43030157</pub-id><pub-id pub-id-type="pmid">34940131</pub-id>
</element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Cobley</surname><given-names>J.N.</given-names></name><name><surname>Fiorello</surname><given-names>M.L.</given-names></name><name><surname>Bailey</surname><given-names>D.M.</given-names></name></person-group><article-title>13 reasons why the brain is susceptible to oxidative stress</article-title><source>Redox Biol.</source><volume>15</volume><year>2018</year><fpage>490</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.redox.2018.01.008</pub-id><pub-id pub-id-type="pmid">29413961</pub-id>
</element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Nayernia</surname><given-names>Z.</given-names></name><name><surname>Jaquet</surname><given-names>V.</given-names></name><name><surname>Krause</surname><given-names>K.-H.</given-names></name></person-group><article-title>New insights on NOX enzymes in the central nervous system</article-title><source>Antioxidants Redox Signal.</source><volume>20</volume><year>2014</year><fpage>2815</fpage><lpage>2837</lpage><pub-id pub-id-type="doi">10.1089/ars.2013.5703</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>P.</given-names></name><name><surname>Khan</surname><given-names>H.</given-names></name><name><surname>Grewal</surname><given-names>A.K.</given-names></name><name><surname>Dua</surname><given-names>K.</given-names></name><name><surname>Singh</surname><given-names>T.G.</given-names></name></person-group><article-title>Therapeutic potential of NOX inhibitors in neuropsychiatric disorders</article-title><source>Psychopharmacology (Berl)</source><volume>240</volume><year>2023</year><fpage>1825</fpage><lpage>1840</lpage><pub-id pub-id-type="doi">10.1007/s00213-023-06424-5</pub-id><pub-id pub-id-type="pmid">37507462</pub-id>
</element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Giulivi</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.-F.</given-names></name><name><surname>Omanska-Klusek</surname><given-names>A.</given-names></name><name><surname>Ross-Inta</surname><given-names>C.</given-names></name><name><surname>Wong</surname><given-names>S.</given-names></name><name><surname>Hertz-Picciotto</surname><given-names>I.</given-names></name><name><surname>Tassone</surname><given-names>F.</given-names></name><name><surname>Pessah</surname><given-names>I.N.</given-names></name></person-group><article-title>Mitochondrial dysfunction in autism</article-title><source>JAMA</source><volume>304</volume><year>2010</year><fpage>2389</fpage><lpage>2396</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.1706</pub-id><pub-id pub-id-type="pmid">21119085</pub-id>
</element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Nadeem</surname><given-names>A.</given-names></name><name><surname>Ahmad</surname><given-names>S.F.</given-names></name><name><surname>Bakheet</surname><given-names>S.A.</given-names></name><name><surname>Al-Harbi</surname><given-names>N.O.</given-names></name><name><surname>Al-Ayadhi</surname><given-names>L.Y.</given-names></name><name><surname>Attia</surname><given-names>S.M.</given-names></name><name><surname>Zoheir</surname><given-names>K.M.A.</given-names></name></person-group><article-title>Toll-like receptor 4 signaling is associated with upregulated NADPH oxidase expression in peripheral T cells of children with autism</article-title><source>Brain Behav. Immun.</source><volume>61</volume><year>2017</year><fpage>146</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2016.12.024</pub-id><pub-id pub-id-type="pmid">28034626</pub-id>
</element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Ro</surname><given-names>M.</given-names></name><name><surname>Park</surname><given-names>J.</given-names></name><name><surname>Nam</surname><given-names>M.</given-names></name><name><surname>Bang</surname><given-names>H.J.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Choi</surname><given-names>K.-S.</given-names></name><name><surname>Kim</surname><given-names>S.K.</given-names></name><name><surname>Chung</surname><given-names>J.-H.</given-names></name><name><surname>Kwack</surname><given-names>K.</given-names></name></person-group><article-title>Association between peroxisomal biogenesis factor 7 and autism spectrum disorders in a Korean population</article-title><source>J. Child Neurol.</source><volume>27</volume><year>2012</year><fpage>1270</fpage><lpage>1275</lpage><pub-id pub-id-type="doi">10.1177/0883073811435507</pub-id><pub-id pub-id-type="pmid">22378669</pub-id>
</element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Clark-Taylor</surname><given-names>T.</given-names></name><name><surname>Clark-Taylor</surname><given-names>B.E.</given-names></name></person-group><article-title>Is autism a disorder of fatty acid metabolism? Possible dysfunction of mitochondrial &#x003b2;-oxidation by long chain acyl-CoA dehydrogenase</article-title><source>Med. Hypotheses</source><volume>62</volume><year>2004</year><fpage>970</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2004.01.011</pub-id><pub-id pub-id-type="pmid">15142659</pub-id>
</element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>J.</given-names></name><name><surname>Dorninger</surname><given-names>F.</given-names></name><name><surname>Forss-Petter</surname><given-names>S.</given-names></name><name><surname>Kunze</surname><given-names>M.</given-names></name></person-group><article-title>Peroxisomes in brain development and function</article-title><source>Biochim. Biophys. Acta</source><volume>1863</volume><year>2016</year><fpage>934</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2015.12.005</pub-id><pub-id pub-id-type="pmid">26686055</pub-id>
</element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Savino</surname><given-names>R.</given-names></name><name><surname>Carotenuto</surname><given-names>M.</given-names></name><name><surname>Polito</surname><given-names>A.N.</given-names></name><name><surname>Noia</surname><given-names>S.D.</given-names></name><name><surname>Albenzio</surname><given-names>M.</given-names></name><name><surname>Scarinci</surname><given-names>A.</given-names></name><name><surname>Ambrosi</surname><given-names>A.</given-names></name><name><surname>Sessa</surname><given-names>F.</given-names></name><name><surname>Tartaglia</surname><given-names>N.</given-names></name><name><surname>Messina</surname><given-names>G.</given-names></name></person-group><article-title>Analyzing the potential biological determinants of autism spectrum disorder: from neuroinflammation to the kynurenine pathway</article-title><source>Brain Sci.</source><volume>10</volume><year>2020</year><fpage>631</fpage><pub-id pub-id-type="doi">10.3390/brainsci10090631</pub-id><pub-id pub-id-type="pmid">32932826</pub-id>
</element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Mor</surname><given-names>A.</given-names></name><name><surname>Tankiewicz-Kwedlo</surname><given-names>A.</given-names></name><name><surname>Krupa</surname><given-names>A.</given-names></name><name><surname>Pawlak</surname><given-names>D.</given-names></name></person-group><article-title>Role of kynurenine pathway in oxidative stress during neurodegenerative disorders</article-title><source>Cells</source><volume>10</volume><year>2021</year><fpage>1603</fpage><pub-id pub-id-type="doi">10.3390/cells10071603</pub-id><pub-id pub-id-type="pmid">34206739</pub-id>
</element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Bryn</surname><given-names>V.</given-names></name><name><surname>Verkerk</surname><given-names>R.</given-names></name><name><surname>Skjeldal</surname><given-names>O.H.</given-names></name><name><surname>Saugstad</surname><given-names>O.D.</given-names></name><name><surname>Ormstad</surname><given-names>H.</given-names></name></person-group><article-title>Kynurenine pathway in autism spectrum disorders in children</article-title><source>Neuropsychobiology</source><volume>76</volume><year>2018</year><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1159/000488157</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Hasegawa</surname><given-names>M.</given-names></name><name><surname>Niijima</surname><given-names>M.</given-names></name><name><surname>Kunisawa</surname><given-names>K.</given-names></name><name><surname>Teshigawara</surname><given-names>T.</given-names></name><name><surname>Kubota</surname><given-names>H.</given-names></name><name><surname>Fujigaki</surname><given-names>S.</given-names></name><name><surname>Fujigaki</surname><given-names>H.</given-names></name><name><surname>Yamamoto</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>H.-C.</given-names></name><name><surname>Saito</surname><given-names>K.</given-names></name><name><surname>Nabeshima</surname><given-names>T.</given-names></name><name><surname>Mouri</surname><given-names>A.</given-names></name></person-group><article-title>Maternal immune activation induces neurodevelopmental impairments of adult offspring through alterations in tryptophane-kynurenine pathway in the placenta</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>737</volume><year>2024</year><object-id pub-id-type="publisher-id">150922</object-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2024.150922</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Ghezzo</surname><given-names>A.</given-names></name><name><surname>Visconti</surname><given-names>P.</given-names></name><name><surname>Abruzzo</surname><given-names>P.M.</given-names></name><name><surname>Bolotta</surname><given-names>A.</given-names></name><name><surname>Ferreri</surname><given-names>C.</given-names></name><name><surname>Gobbi</surname><given-names>G.</given-names></name><name><surname>Malisardi</surname><given-names>G.</given-names></name><name><surname>Manfredini</surname><given-names>S.</given-names></name><name><surname>Marini</surname><given-names>M.</given-names></name><name><surname>Nanetti</surname><given-names>L.</given-names></name><name><surname>Pipitone</surname><given-names>E.</given-names></name><name><surname>Raffaelli</surname><given-names>F.</given-names></name><name><surname>Resca</surname><given-names>F.</given-names></name><name><surname>Vignini</surname><given-names>A.</given-names></name><name><surname>Mazzanti</surname><given-names>L.</given-names></name></person-group><article-title>Oxidative stress and erythrocyte membrane alterations in children with autism: correlation with clinical features</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e66418</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0066418</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Pop</surname><given-names>B.</given-names></name><name><surname>&#x00218;tefan Niculae</surname><given-names>A.</given-names></name><name><surname>Pop</surname><given-names>T.L.</given-names></name><name><surname>R&#x00103;chi&#x0015f;an</surname><given-names>A.L.</given-names></name></person-group><article-title>Individuals with autism have higher 8-Iso-PGF2&#x003b1; levels than controls, but no correlation with quantitative assay of Paraoxonase 1 serum levels</article-title><source>Metab. Brain Dis.</source><volume>32</volume><year>2017</year><fpage>1943</fpage><lpage>1950</lpage><pub-id pub-id-type="doi">10.1007/s11011-017-0083-4</pub-id><pub-id pub-id-type="pmid">28808839</pub-id>
</element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Signorini</surname><given-names>C.</given-names></name><name><surname>Felice</surname><given-names>C.D.</given-names></name><name><surname>Durand</surname><given-names>T.</given-names></name><name><surname>Oger</surname><given-names>C.</given-names></name><name><surname>Galano</surname><given-names>J.-M.</given-names></name><name><surname>Leoncini</surname><given-names>S.</given-names></name><name><surname>Pecorelli</surname><given-names>A.</given-names></name><name><surname>Valacchi</surname><given-names>G.</given-names></name><name><surname>Ciccoli</surname><given-names>L.</given-names></name><name><surname>Hayek</surname><given-names>J.</given-names></name></person-group><article-title>Isoprostanes and 4-Hydroxy-2-nonenal: markers or mediators of disease? Focus on rett syndrome as a model of autism spectrum disorder</article-title><source>Oxid. Med. Cell. Longev.</source><volume>2013</volume><year>2013</year><object-id pub-id-type="publisher-id">343824</object-id><pub-id pub-id-type="doi">10.1155/2013/343824</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Ming</surname><given-names>X.</given-names></name><name><surname>Stein</surname><given-names>T.P.</given-names></name><name><surname>Brimacombe</surname><given-names>M.</given-names></name><name><surname>Johnson</surname><given-names>W.G.</given-names></name><name><surname>Lambert</surname><given-names>G.H.</given-names></name><name><surname>Wagner</surname><given-names>G.C.</given-names></name></person-group><article-title>Increased excretion of a lipid peroxidation biomarker in autism</article-title><source>Prostagl. Leukot. Essent. Fat. Acids</source><volume>73</volume><year>2005</year><fpage>379</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.plefa.2005.06.002</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Frackowiak</surname><given-names>J.</given-names></name><name><surname>Mazur-Kolecka</surname><given-names>B.</given-names></name><name><surname>Schanen</surname><given-names>N.C.</given-names></name><name><surname>Brown</surname><given-names>W.T.</given-names></name><name><surname>Wegiel</surname><given-names>J.</given-names></name></person-group><article-title>The link between intraneuronal N-truncated amyloid-&#x003b2; peptide and oxidatively modified lipids in idiopathic autism and dup(15q11.2-q13)/autism</article-title><source>Acta Neuropathologica Commun.</source><volume>1</volume><year>2013</year><fpage>61</fpage><pub-id pub-id-type="doi">10.1186/2051-5960-1-61</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>A.</given-names></name><name><surname>Chauhan</surname><given-names>V.</given-names></name><name><surname>Brown</surname><given-names>W.T.</given-names></name><name><surname>Cohen</surname><given-names>I.</given-names></name></person-group><article-title>Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin - the antioxidant proteins</article-title><source>Life Sci.</source><volume>75</volume><year>2004</year><fpage>2539</fpage><lpage>2549</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2004.04.038</pub-id><pub-id pub-id-type="pmid">15363659</pub-id>
</element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Al-Gadani</surname><given-names>Y.</given-names></name><name><surname>El-Ansary</surname><given-names>A.</given-names></name><name><surname>Attas</surname><given-names>O.</given-names></name><name><surname>Al-Ayadhi</surname><given-names>L.</given-names></name></person-group><article-title>Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children</article-title><source>Clin. Biochem.</source><volume>42</volume><year>2009</year><fpage>1032</fpage><lpage>1040</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2009.03.011</pub-id><pub-id pub-id-type="pmid">19306862</pub-id>
</element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Essa</surname><given-names>M.M.</given-names></name><name><surname>Guillemin</surname><given-names>G.J.</given-names></name><name><surname>Waly</surname><given-names>M.I.</given-names></name><name><surname>Al-Sharbati</surname><given-names>M.M.</given-names></name><name><surname>Al-Farsi</surname><given-names>Y.M.</given-names></name><name><surname>Hakkim</surname><given-names>F.L.</given-names></name><name><surname>Ali</surname><given-names>A.</given-names></name><name><surname>Al-Shafaee</surname><given-names>M.S.</given-names></name></person-group><article-title>Increased markers of oxidative stress in autistic children of the sultanate of Oman</article-title><source>Biol. Trace Elem. Res.</source><volume>147</volume><year>2012</year><fpage>25</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1007/s12011-011-9280-x</pub-id><pub-id pub-id-type="pmid">22127832</pub-id>
</element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Meguid</surname><given-names>N.A.</given-names></name><name><surname>Dardir</surname><given-names>A.A.</given-names></name><name><surname>Abdel-Raouf</surname><given-names>E.R.</given-names></name><name><surname>Hashish</surname><given-names>A.</given-names></name></person-group><article-title>Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation</article-title><source>Biol. Trace Elem. Res.</source><volume>143</volume><year>2011</year><fpage>58</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1007/s12011-010-8840-9</pub-id><pub-id pub-id-type="pmid">20845086</pub-id>
</element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez-Fraguela</surname><given-names>M.E.</given-names></name><name><surname>Hung</surname><given-names>M.-L.D.</given-names></name><name><surname>Vera</surname><given-names>H.</given-names></name><name><surname>Maragoto</surname><given-names>C.</given-names></name><name><surname>Noris</surname><given-names>E.</given-names></name><name><surname>Blanco</surname><given-names>L.</given-names></name><name><surname>Galvizu</surname><given-names>R.</given-names></name><name><surname>Robinson</surname><given-names>M.</given-names></name></person-group><article-title>Oxidative stress markers in children with autism spectrum disorders</article-title><source>J. Adv. Med. Med. Res.</source><year>2013</year><fpage>307</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.9734/BJMMR/2013/2335</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>El-Ansary</surname><given-names>A.</given-names></name><name><surname>Bj&#x000f8;rklund</surname><given-names>G.</given-names></name><name><surname>Chirumbolo</surname><given-names>S.</given-names></name><name><surname>Alnakhli</surname><given-names>O.M.</given-names></name></person-group><article-title>Predictive value of selected biomarkers related to metabolism and oxidative stress in children with autism spectrum disorder</article-title><source>Metab. Brain Dis.</source><volume>32</volume><year>2017</year><fpage>1209</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1007/s11011-017-0029-x</pub-id><pub-id pub-id-type="pmid">28497358</pub-id>
</element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Parellada</surname><given-names>M.</given-names></name><name><surname>Moreno</surname><given-names>C.</given-names></name><name><surname>Mac-Dowell</surname><given-names>K.</given-names></name><name><surname>Leza</surname><given-names>J.C.</given-names></name><name><surname>Giraldez</surname><given-names>M.</given-names></name><name><surname>Bail&#x000f3;n</surname><given-names>C.</given-names></name><name><surname>Castro</surname><given-names>C.</given-names></name><name><surname>Miranda-Azpiazu</surname><given-names>P.</given-names></name><name><surname>Fraguas</surname><given-names>D.</given-names></name><name><surname>Arango</surname><given-names>C.</given-names></name></person-group><article-title>Plasma antioxidant capacity is reduced in Asperger syndrome</article-title><source>J. Psychiatr. Res.</source><volume>46</volume><year>2012</year><fpage>394</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2011.10.004</pub-id><pub-id pub-id-type="pmid">22225920</pub-id>
</element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Damodaran</surname><given-names>L.P.M.</given-names></name><name><surname>Arumugam</surname><given-names>G.</given-names></name></person-group><article-title>Urinary oxidative stress markers in children with autism</article-title><source>Redox Rep. : Commun. Free Radical Res.</source><volume>16</volume><year>2013</year><fpage>216</fpage><pub-id pub-id-type="doi">10.1179/1351000211Y.0000000012</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Pecorelli</surname><given-names>A.</given-names></name><name><surname>Leoncini</surname><given-names>S.</given-names></name><name><surname>Felice</surname><given-names>C.D.</given-names></name><name><surname>Signorini</surname><given-names>C.</given-names></name><name><surname>Cerrone</surname><given-names>C.</given-names></name><name><surname>Valacchi</surname><given-names>G.</given-names></name><name><surname>Ciccoli</surname><given-names>L.</given-names></name><name><surname>Hayek</surname><given-names>J.</given-names></name></person-group><article-title>Non-protein-bound iron and 4-hydroxynonenal protein adducts in classic autism</article-title><source>Brain Dev.</source><volume>35</volume><year>2013</year><fpage>146</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2012.03.011</pub-id><pub-id pub-id-type="pmid">22534237</pub-id>
</element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>A.</given-names></name><name><surname>Niu</surname><given-names>L.</given-names></name><name><surname>Min</surname><given-names>J.</given-names></name><name><surname>Meng</surname><given-names>X.</given-names></name><name><surname>Liao</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name></person-group><article-title>Redox proteomic identification of carbonylated proteins in autism plasma: insight into oxidative stress and its related biomarkers in autism</article-title><source>Clin. Proteom.</source><volume>14</volume><year>2017</year><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/s12014-017-9138-0</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Sajdel-Sulkowska</surname><given-names>E.M.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>McGinnis</surname><given-names>W.</given-names></name><name><surname>Koibuchi</surname><given-names>N.</given-names></name></person-group><article-title>Brain region-specific changes in oxidative stress and neurotrophin levels in autism spectrum disorders (ASD)</article-title><source>Cerebellum</source><volume>10</volume><year>2011</year><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1007/s12311-010-0223-4</pub-id><pub-id pub-id-type="pmid">20967576</pub-id>
</element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Sajdel-Sulkowska</surname><given-names>E.M.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Koibuchi</surname><given-names>N.</given-names></name></person-group><article-title>Increase in cerebellar neurotrophin-3 and oxidative stress markers in autism</article-title><source>Cerebellum</source><volume>8</volume><year>2009</year><fpage>366</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1007/s12311-009-0105-9</pub-id><pub-id pub-id-type="pmid">19357934</pub-id>
</element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>Frye</surname><given-names>R.E.</given-names></name><name><surname>Rose</surname><given-names>S.</given-names></name><name><surname>Voinsky</surname><given-names>I.</given-names></name><name><surname>Gurwitz</surname><given-names>D.</given-names></name></person-group><article-title>Nitrosative stress in autism: supportive evidence and implications for mitochondrial dysfunction</article-title><source>Adv. Sci.</source><volume>11</volume><year>2024</year><object-id pub-id-type="publisher-id">e2304439</object-id><pub-id pub-id-type="doi">10.1002/advs.202304439</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>S&#x000f6;&#x0011f;&#x000fc;t</surname><given-names>S.</given-names></name><name><surname>Zoro&#x0011f;lu</surname><given-names>S.S.</given-names></name><name><surname>Ozyurt</surname><given-names>H.</given-names></name><name><surname>Yilmaz</surname><given-names>H.R.</given-names></name><name><surname>Ozu&#x0011f;urlu</surname><given-names>F.</given-names></name><name><surname>Sivasli</surname><given-names>E.</given-names></name><name><surname>Yetkin</surname><given-names>O.</given-names></name><name><surname>Yanik</surname><given-names>M.</given-names></name><name><surname>Tutkun</surname><given-names>H.</given-names></name><name><surname>Sava&#x0015f;</surname><given-names>H.A.</given-names></name><name><surname>Tarak&#x000e7;io&#x0011f;lu</surname><given-names>M.</given-names></name><name><surname>Akyol</surname><given-names>O.</given-names></name></person-group><article-title>Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism</article-title><source>Clin. Chim. Acta</source><volume>331</volume><year>2003</year><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/s0009-8981(03)00119-0</pub-id><pub-id pub-id-type="pmid">12691871</pub-id>
</element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name><surname>Frye</surname><given-names>R.E.</given-names></name><name><surname>Huffman</surname><given-names>L.C.</given-names></name><name><surname>Elliott</surname><given-names>G.R.</given-names></name></person-group><article-title>Tetrahydrobiopterin as a novel therapeutic intervention for autism</article-title><source>Neurotherapeutics</source><volume>7</volume><year>2010</year><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/j.nurt.2010.05.004</pub-id><pub-id pub-id-type="pmid">20643376</pub-id>
</element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Main</surname><given-names>P.A.E.</given-names></name><name><surname>Thomas</surname><given-names>P.</given-names></name><name><surname>Esterman</surname><given-names>A.</given-names></name><name><surname>Fenech</surname><given-names>M.F.</given-names></name></person-group><article-title>Necrosis is increased in lymphoblastoid cell lines from children with autism compared with their non-autistic siblings under conditions of oxidative and nitrosative stress</article-title><source>Mutagenesis</source><volume>28</volume><year>2013</year><fpage>475</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1093/mutage/get025</pub-id><pub-id pub-id-type="pmid">23766106</pub-id>
</element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Shmarina</surname><given-names>G.V.</given-names></name><name><surname>Ershova</surname><given-names>E.S.</given-names></name><name><surname>Simashkova</surname><given-names>N.V.</given-names></name><name><surname>Nikitina</surname><given-names>S.G.</given-names></name><name><surname>Chudakova</surname><given-names>J.M.</given-names></name><name><surname>Veiko</surname><given-names>N.N.</given-names></name><name><surname>Porokhovnik</surname><given-names>L.N.</given-names></name><name><surname>Basova</surname><given-names>A.Y.</given-names></name><name><surname>Shaposhnikova</surname><given-names>A.F.</given-names></name><name><surname>Pukhalskaya</surname><given-names>D.A.</given-names></name><name><surname>Pisarev</surname><given-names>V.M.</given-names></name><name><surname>Korovina</surname><given-names>N.J.</given-names></name><name><surname>Gorbachevskaya</surname><given-names>N.L.</given-names></name><name><surname>Dolgikh</surname><given-names>O.A.</given-names></name><name><surname>Bogush</surname><given-names>M.</given-names></name><name><surname>Kutsev</surname><given-names>S.I.</given-names></name><name><surname>Kostyuk</surname><given-names>S.V.</given-names></name></person-group><article-title>Oxidized cell-free DNA as a stress-signaling factor activating the chronic inflammatory process in patients with autism spectrum disorders</article-title><source>J. Neuroinflammation</source><volume>17</volume><year>2020</year><fpage>212</fpage><pub-id pub-id-type="doi">10.1186/s12974-020-01881-7</pub-id><pub-id pub-id-type="pmid">32677958</pub-id>
</element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="other" id="sref78"><person-group person-group-type="author"><name><surname>Ismael</surname><given-names>H.M.</given-names></name><name><surname>Ismail</surname><given-names>P.A.</given-names></name></person-group><article-title>The utility of 8-Hydroxydeoxyguanosine and 8-Oxoguanine DNA glycosylase as a novel diagnostic marker for autistic children</article-title><comment>2025.01.15.25320384</comment><pub-id pub-id-type="doi">10.1101/2025.01.15.25320384</pub-id><year>2025</year></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Aquilano</surname><given-names>K.</given-names></name><name><surname>Baldelli</surname><given-names>S.</given-names></name><name><surname>Ciriolo</surname><given-names>M.R.</given-names></name></person-group><article-title>Glutathione: new roles in redox signaling for an old antioxidant</article-title><source>Front. Pharmacol.</source><volume>5</volume><year>2014</year><pub-id pub-id-type="doi">10.3389/fphar.2014.00196</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>S.</given-names></name><name><surname>Melnyk</surname><given-names>S.</given-names></name><name><surname>Trusty</surname><given-names>T.A.</given-names></name><name><surname>Pavliv</surname><given-names>O.</given-names></name><name><surname>Seidel</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Nick</surname><given-names>T.</given-names></name><name><surname>James</surname><given-names>S.J.</given-names></name></person-group><article-title>Intracellular and extracellular redox status and free radical generation in primary immune cells from children with autism</article-title><source>Autism. Res. Treat</source><volume>2012</volume><year>2012</year><object-id pub-id-type="publisher-id">986519</object-id><pub-id pub-id-type="doi">10.1155/2012/986519</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J.B.</given-names></name><name><surname>Audhya</surname><given-names>T.</given-names></name><name><surname>McDonough-Means</surname><given-names>S.</given-names></name><name><surname>Rubin</surname><given-names>R.A.</given-names></name><name><surname>Quig</surname><given-names>D.</given-names></name><name><surname>Geis</surname><given-names>E.</given-names></name><name><surname>Gehn</surname><given-names>E.</given-names></name><name><surname>Loresto</surname><given-names>M.</given-names></name><name><surname>Mitchell</surname><given-names>J.</given-names></name><name><surname>Atwood</surname><given-names>S.</given-names></name><name><surname>Barnhouse</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>W.</given-names></name></person-group><article-title>Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity</article-title><source>Nutr. Metab.</source><volume>8</volume><year>2011</year><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/1743-7075-8-34</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name><surname>Mandic-Maravic</surname><given-names>V.</given-names></name><name><surname>Mitkovic-Voncina</surname><given-names>M.</given-names></name><name><surname>Pljesa-Ercegovac</surname><given-names>M.</given-names></name><name><surname>Savic-Radojevic</surname><given-names>A.</given-names></name><name><surname>Djordjevic</surname><given-names>M.</given-names></name><name><surname>Ercegovac</surname><given-names>M.</given-names></name><name><surname>Pekmezovic</surname><given-names>T.</given-names></name><name><surname>Simic</surname><given-names>T.</given-names></name><name><surname>Pejovic-Milovancevic</surname><given-names>M.</given-names></name></person-group><article-title>Glutathione S-transferase polymorphisms and clinical characteristics in autism spectrum disorders</article-title><source>Front. Psychiatr.</source><volume>12</volume><year>2021</year><object-id pub-id-type="publisher-id">672389</object-id><pub-id pub-id-type="doi">10.3389/fpsyt.2021.672389</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Jia</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name></person-group><article-title>Serum levels of SOD and risk of autism spectrum disorder: a case-control study</article-title><source>Int. J. Dev. Neurosci.</source><volume>51</volume><year>2016</year><fpage>12</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.ijdevneu.2016.04.004</pub-id><pub-id pub-id-type="pmid">27091401</pub-id>
</element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name><surname>Zoroglu</surname><given-names>S.S.</given-names></name><name><surname>Armutcu</surname><given-names>F.</given-names></name><name><surname>Ozen</surname><given-names>S.</given-names></name><name><surname>Gurel</surname><given-names>A.</given-names></name><name><surname>Sivasli</surname><given-names>E.</given-names></name><name><surname>Yetkin</surname><given-names>O.</given-names></name><name><surname>Meram</surname><given-names>I.</given-names></name></person-group><article-title>Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism</article-title><source>Eur. Arch. Psychiatr. Clin. Neurosci.</source><volume>254</volume><year>2004</year><fpage>143</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1007/s00406-004-0456-7</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name><surname>Khaliulin</surname><given-names>I.</given-names></name><name><surname>Hamoudi</surname><given-names>W.</given-names></name><name><surname>Amal</surname><given-names>H.</given-names></name></person-group><article-title>The multifaceted role of mitochondria in autism spectrum disorder</article-title><source>Mol. Psychiatr.</source><volume>30</volume><year>2025</year><fpage>629</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1038/s41380-024-02725-z</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>P.</given-names></name><name><surname>Stamler</surname><given-names>J.S.</given-names></name></person-group><article-title>Enzymatic mechanisms regulating protein S-nitrosylation: implications in health and disease</article-title><source>J. Mol. Med. (Berl.)</source><volume>90</volume><year>2012</year><fpage>233</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1007/s00109-012-0878-z</pub-id><pub-id pub-id-type="pmid">22361849</pub-id>
</element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>M.K.</given-names></name><name><surname>Ojha</surname><given-names>S.K.</given-names></name><name><surname>Kartawy</surname><given-names>M.</given-names></name><name><surname>Hamoudi</surname><given-names>W.</given-names></name><name><surname>Choudhary</surname><given-names>A.</given-names></name><name><surname>Stern</surname><given-names>S.</given-names></name><name><surname>Aran</surname><given-names>A.</given-names></name><name><surname>Amal</surname><given-names>H.</given-names></name></person-group><article-title>The NO answer for autism spectrum disorder</article-title><source>Adv. Sci.</source><volume>10</volume><year>2023</year><object-id pub-id-type="publisher-id">2205783</object-id><pub-id pub-id-type="doi">10.1002/advs.202205783</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name><surname>Kartawy</surname><given-names>M.</given-names></name><name><surname>Khaliulin</surname><given-names>I.</given-names></name><name><surname>Amal</surname><given-names>H.</given-names></name></person-group><article-title>Systems biology reveals S-Nitrosylation-Dependent regulation of mitochondrial functions in mice with Shank3 mutation associated with autism spectrum disorder</article-title><source>Brain Sci.</source><volume>11</volume><year>2021</year><fpage>677</fpage><pub-id pub-id-type="doi">10.3390/brainsci11060677</pub-id><pub-id pub-id-type="pmid">34064215</pub-id>
</element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>S.</given-names></name><name><surname>Lipton</surname><given-names>S.A.</given-names></name></person-group><article-title>S-Nitrosylation in neurogenesis and neuronal development</article-title><source>Biochim. Biophys. Acta Gen. Subj.</source><volume>1850</volume><year>2015</year><fpage>1588</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2014.12.013</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>M.K.</given-names></name><name><surname>Kartawy</surname><given-names>M.</given-names></name><name><surname>Amal</surname><given-names>H.</given-names></name></person-group><article-title>The role of nitric oxide in brain disorders: autism spectrum disorder and other psychiatric, neurological, and neurodegenerative disorders</article-title><source>Redox Biol.</source><volume>34</volume><year>2020</year><object-id pub-id-type="publisher-id">101567</object-id><pub-id pub-id-type="doi">10.1016/j.redox.2020.101567</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name><surname>Rojas-Charry</surname><given-names>L.</given-names></name><name><surname>Nardi</surname><given-names>L.</given-names></name><name><surname>Methner</surname><given-names>A.</given-names></name><name><surname>Schmeisser</surname><given-names>M.J.</given-names></name></person-group><article-title>Abnormalities of synaptic mitochondria in autism spectrum disorder and related neurodevelopmental disorders</article-title><source>J. Mol. Med. (Berl.)</source><volume>99</volume><year>2021</year><fpage>161</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1007/s00109-020-02018-2</pub-id><pub-id pub-id-type="pmid">33340060</pub-id>
</element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name><surname>Maalouf</surname><given-names>M.</given-names></name><name><surname>Rho</surname><given-names>J.M.</given-names></name></person-group><article-title>Oxidative impairment of hippocampal long-term potentiation involves activation of protein phosphatase 2A and is prevented by ketone bodies</article-title><source>J. Neurosci. Res.</source><volume>86</volume><year>2008</year><fpage>3322</fpage><lpage>3330</lpage><pub-id pub-id-type="doi">10.1002/jnr.21782</pub-id><pub-id pub-id-type="pmid">18646208</pub-id>
</element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>N.H.</given-names></name><name><surname>Janzarik</surname><given-names>W.G.</given-names></name><name><surname>Delvendahl</surname><given-names>I.</given-names></name><name><surname>M&#x000fc;nchau</surname><given-names>A.</given-names></name><name><surname>Biscaldi</surname><given-names>M.</given-names></name><name><surname>Mainberger</surname><given-names>F.</given-names></name><name><surname>B&#x000e4;umer</surname><given-names>T.</given-names></name><name><surname>Rauh</surname><given-names>R.</given-names></name><name><surname>Mall</surname><given-names>V.</given-names></name></person-group><article-title>Impaired induction of long-term potentiation-like plasticity in patients with high-functioning autism and Asperger syndrome</article-title><source>Dev. Med. Child Neurol.</source><volume>55</volume><year>2013</year><fpage>83</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1111/dmcn.12012</pub-id><pub-id pub-id-type="pmid">23157428</pub-id>
</element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name><surname>Nisar</surname><given-names>S.</given-names></name><name><surname>Bhat</surname><given-names>A.A.</given-names></name><name><surname>Masoodi</surname><given-names>T.</given-names></name><name><surname>Hashem</surname><given-names>S.</given-names></name><name><surname>Akhtar</surname><given-names>S.</given-names></name><name><surname>Ali</surname><given-names>T.A.</given-names></name><name><surname>Amjad</surname><given-names>S.</given-names></name><name><surname>Chawla</surname><given-names>S.</given-names></name><name><surname>Bagga</surname><given-names>P.</given-names></name><name><surname>Frenneaux</surname><given-names>M.P.</given-names></name><name><surname>Reddy</surname><given-names>R.</given-names></name><name><surname>Fakhro</surname><given-names>K.</given-names></name><name><surname>Haris</surname><given-names>M.</given-names></name></person-group><article-title>Genetics of glutamate and its receptors in autism spectrum disorder</article-title><source>Mol. Psychiatr.</source><volume>27</volume><year>2022</year><fpage>2380</fpage><lpage>2392</lpage><pub-id pub-id-type="doi">10.1038/s41380-022-01506-w</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name><surname>El-Ansary</surname><given-names>A.</given-names></name></person-group><article-title>Data of multiple regressions analysis between selected biomarkers related to glutamate excitotoxicity and oxidative stress in Saudi autistic patients</article-title><source>Data Brief</source><volume>7</volume><year>2016</year><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.dib.2016.02.025</pub-id><pub-id pub-id-type="pmid">26933667</pub-id>
</element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name><surname>Gasier</surname><given-names>H.G.</given-names></name><name><surname>Demchenko</surname><given-names>I.T.</given-names></name><name><surname>Tatro</surname><given-names>L.G.</given-names></name><name><surname>Piantadosi</surname><given-names>C.A.</given-names></name></person-group><article-title>S-nitrosylation of GAD65 is implicated in decreased GAD activity and oxygen-induced seizures</article-title><source>Neurosci. Lett.</source><volume>653</volume><year>2017</year><fpage>283</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2017.05.067</pub-id><pub-id pub-id-type="pmid">28579483</pub-id>
</element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name><surname>Alabdali</surname><given-names>A.</given-names></name><name><surname>Ben Bacha</surname><given-names>A.</given-names></name><name><surname>Alonazi</surname><given-names>M.</given-names></name><name><surname>Al-Ayadhi</surname><given-names>L.Y.</given-names></name><name><surname>Alanazi</surname><given-names>A.S.J.</given-names></name><name><surname>El&#x02010;Ansary</surname><given-names>A.</given-names></name></person-group><article-title>Comparative evaluation of certain biomarkers emphasizing abnormal GABA inhibitory effect and glutamate excitotoxicity in autism spectrum disorders</article-title><source>Front. Psychiatr.</source><volume>16</volume><year>2025</year><object-id pub-id-type="publisher-id">1562631</object-id><pub-id pub-id-type="doi">10.3389/fpsyt.2025.1562631</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name><surname>Canning</surname><given-names>P.</given-names></name><name><surname>Sorrell</surname><given-names>F.J.</given-names></name><name><surname>Bullock</surname><given-names>A.N.</given-names></name></person-group><article-title>Structural basis of Keap1 interactions with Nrf2</article-title><source>Free Radic. Biol. Med.</source><volume>88</volume><year>2015</year><fpage>101</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.05.034</pub-id><pub-id pub-id-type="pmid">26057936</pub-id>
</element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Q.</given-names></name></person-group><article-title>Role of Nrf2 in oxidative stress and toxicity</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><volume>53</volume><year>2013</year><fpage>401</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-011112-140320</pub-id><pub-id pub-id-type="pmid">23294312</pub-id>
</element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name><surname>Horie</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Inoue</surname><given-names>J.</given-names></name><name><surname>Iso</surname><given-names>T.</given-names></name><name><surname>Wells</surname><given-names>G.</given-names></name><name><surname>Moore</surname><given-names>T.W.</given-names></name><name><surname>Mizushima</surname><given-names>T.</given-names></name><name><surname>Dinkova-Kostova</surname><given-names>A.T.</given-names></name><name><surname>Kasai</surname><given-names>T.</given-names></name><name><surname>Kamei</surname><given-names>T.</given-names></name><name><surname>Koshiba</surname><given-names>S.</given-names></name><name><surname>Yamamoto</surname><given-names>M.</given-names></name></person-group><article-title>Molecular basis for the disruption of Keap1-Nrf2 interaction via Hinge &#x00026; Latch mechanism</article-title><source>Commun. Biol.</source><volume>4</volume><year>2021</year><pub-id pub-id-type="doi">10.1038/S42003-021-02100-6</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name><surname>Cuadrado</surname><given-names>A.</given-names></name></person-group><article-title>Structural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3/&#x003b2;-TrCP</article-title><source>Free Radic. Biol. Med.</source><volume>88</volume><year>2015</year><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.04.029</pub-id><pub-id pub-id-type="pmid">25937177</pub-id>
</element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name><surname>Silva-Islas</surname><given-names>C.A.</given-names></name><name><surname>Maldonado</surname><given-names>P.D.</given-names></name></person-group><article-title>Canonical and non-canonical mechanisms of Nrf2 activation</article-title><source>Pharmacol. Res.</source><volume>134</volume><year>2018</year><fpage>92</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.06.013</pub-id><pub-id pub-id-type="pmid">29913224</pub-id>
</element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Lv</surname><given-names>Y.-F.</given-names></name><name><surname>Zhao</surname><given-names>J.-L.</given-names></name><name><surname>You</surname><given-names>Q.-D.</given-names></name><name><surname>Jiang</surname><given-names>Z.-Y.</given-names></name></person-group><article-title>Regulation of Nrf2 by phosphorylation: consequences for biological function and therapeutic implications</article-title><source>Free Radic. Biol. Med.</source><volume>168</volume><year>2021</year><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.03.034</pub-id><pub-id pub-id-type="pmid">33794311</pub-id>
</element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name><surname>Dayalan Naidu</surname><given-names>S.</given-names></name><name><surname>Dinkova-Kostova</surname><given-names>A.T.</given-names></name></person-group><article-title>KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease</article-title><source>Open Biol.</source><volume>10</volume><year>2020</year><pub-id pub-id-type="doi">10.1098/RSOB.200105/</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name><surname>Theodore</surname><given-names>M.</given-names></name><name><surname>Kawai</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Kleshchenko</surname><given-names>Y.</given-names></name><name><surname>Reddy</surname><given-names>S.P.</given-names></name><name><surname>Villalta</surname><given-names>F.</given-names></name><name><surname>Arinze</surname><given-names>I.J.</given-names></name></person-group><article-title>Multiple nuclear localization signals function in the nuclear import of the transcription factor Nrf2</article-title><source>J. Biol. Chem.</source><volume>283</volume><year>2008</year><fpage>8984</fpage><lpage>8994</lpage><pub-id pub-id-type="doi">10.1074/jbc.M709040200</pub-id><pub-id pub-id-type="pmid">18238777</pub-id>
</element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name><surname>Hirotsu</surname><given-names>Y.</given-names></name><name><surname>Katsuoka</surname><given-names>F.</given-names></name><name><surname>Funayama</surname><given-names>R.</given-names></name><name><surname>Nagashima</surname><given-names>T.</given-names></name><name><surname>Nishida</surname><given-names>Y.</given-names></name><name><surname>Nakayama</surname><given-names>K.</given-names></name><name><surname>Douglas Engel</surname><given-names>J.</given-names></name><name><surname>Yamamoto</surname><given-names>M.</given-names></name></person-group><article-title>Nrf2&#x02013;MafG heterodimers contribute globally to antioxidant and metabolic networks</article-title><source>Nucleic Acids Res.</source><volume>40</volume><year>2012</year><fpage>10228</fpage><lpage>10239</lpage><pub-id pub-id-type="doi">10.1093/nar/gks827</pub-id><pub-id pub-id-type="pmid">22965115</pub-id>
</element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Lai</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Sun</surname><given-names>F.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Xiong</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Gong</surname><given-names>Q.</given-names></name><name><surname>Ren</surname><given-names>B.</given-names></name><name><surname>Weng</surname><given-names>J.</given-names></name><name><surname>Eizirik</surname><given-names>D.L.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>C.Y.</given-names></name></person-group><article-title>Both conditional ablation and overexpression of E2 SUMO-conjugating enzyme (UBC9) in mouse pancreatic beta cells result in impaired beta cell function</article-title><source>Diabetologia</source><volume>61</volume><year>2018</year><fpage>881</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1007/S00125-017-4523-9</pub-id><pub-id pub-id-type="pmid">29299635</pub-id>
</element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Chin</surname><given-names>Y.E.</given-names></name><name><surname>Zhang</surname><given-names>D.D.</given-names></name></person-group><article-title>Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response</article-title><source>Mol. Cell Biol.</source><volume>29</volume><year>2009</year><fpage>2658</fpage><lpage>2672</lpage><pub-id pub-id-type="doi">10.1128/MCB.01639-08</pub-id><pub-id pub-id-type="pmid">19273602</pub-id>
</element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name><surname>Davinelli</surname><given-names>S.</given-names></name><name><surname>Medoro</surname><given-names>A.</given-names></name><name><surname>Intrieri</surname><given-names>M.</given-names></name><name><surname>Saso</surname><given-names>L.</given-names></name><name><surname>Scapagnini</surname><given-names>G.</given-names></name><name><surname>Kang</surname><given-names>J.X.</given-names></name></person-group><article-title>Targeting NRF2-KEAP1 axis by Omega-3 fatty acids and their derivatives: emerging opportunities against aging and diseases</article-title><source>Free Radical Biol. Med.</source><volume>193</volume><year>2022</year><fpage>736</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1016/J.FREERADBIOMED.2022.11.017</pub-id><pub-id pub-id-type="pmid">36402440</pub-id>
</element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name><surname>Medoro</surname><given-names>A.</given-names></name><name><surname>Saso</surname><given-names>L.</given-names></name><name><surname>Scapagnini</surname><given-names>G.</given-names></name><name><surname>Davinelli</surname><given-names>S.</given-names></name></person-group><article-title>NRF2 signaling pathway and telomere length in aging and age-related diseases</article-title><source>Mol. Cell. Biochem.</source><year>2023</year><pub-id pub-id-type="doi">10.1007/S11010-023-04878-X</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>K.C.</given-names></name><name><surname>Cui</surname><given-names>J.Y.</given-names></name><name><surname>Klaassen</surname><given-names>C.D.</given-names></name></person-group><article-title>Beneficial role of Nrf2 in regulating NADPH generation and consumption</article-title><source>Toxicol. Sci.</source><volume>123</volume><year>2011</year><fpage>590</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfr183</pub-id><pub-id pub-id-type="pmid">21775727</pub-id>
</element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name><surname>Thimmulappa</surname><given-names>R.K.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Rangasamy</surname><given-names>T.</given-names></name><name><surname>Reddy</surname><given-names>S.P.</given-names></name><name><surname>Yamamoto</surname><given-names>M.</given-names></name><name><surname>Kensler</surname><given-names>T.W.</given-names></name><name><surname>Biswal</surname><given-names>S.</given-names></name></person-group><article-title>Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis</article-title><source>J. Clin. Investig.</source><volume>116</volume><year>2016</year><fpage>984</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1172/JCI25790</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G.-H.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Shen</surname><given-names>X.</given-names></name></person-group><article-title>NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK</article-title><source>Biochim. Biophys. Acta</source><volume>1783</volume><year>2008</year><fpage>713</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2008.01.002</pub-id><pub-id pub-id-type="pmid">18241676</pub-id>
</element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>N.K.</given-names></name><name><surname>Fitzgerald</surname><given-names>H.K.</given-names></name><name><surname>Dunne</surname><given-names>A.</given-names></name></person-group><article-title>Regulation of inflammation by the antioxidant haem oxygenase 1</article-title><source>Nat. Rev. Immunol.</source><volume>21</volume><year>2021</year><fpage>411</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-00491-x</pub-id><pub-id pub-id-type="pmid">33514947</pub-id>
</element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name><surname>Davinelli</surname><given-names>S.</given-names></name><name><surname>Saso</surname><given-names>L.</given-names></name><name><surname>D&#x02019;angeli</surname><given-names>F.</given-names></name><name><surname>Calabrese</surname><given-names>V.</given-names></name><name><surname>Intrieri</surname><given-names>M.</given-names></name><name><surname>Scapagnini</surname><given-names>G.</given-names></name></person-group><article-title>Astaxanthin as a modulator of Nrf2, NF-&#x003ba;B, and their crosstalk: molecular mechanisms and possible clinical applications</article-title><source>Molecules (Basel, Switzerland)</source><volume>27</volume><year>2022</year><pub-id pub-id-type="doi">10.3390/MOLECULES27020502</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name><surname>Calabrese</surname><given-names>E.J.</given-names></name><name><surname>Kozumbo</surname><given-names>W.J.</given-names></name></person-group><article-title>The hormetic dose-response mechanism: Nrf2 activation</article-title><source>Pharmacol. Res.</source><volume>167</volume><year>2021</year><object-id pub-id-type="publisher-id">105526</object-id><pub-id pub-id-type="doi">10.1016/j.phrs.2021.105526</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>H.-Y.</given-names></name><name><surname>Marzec</surname><given-names>J.</given-names></name><name><surname>Kleeberger</surname><given-names>S.R.</given-names></name></person-group><article-title>Functional polymorphisms in Nrf2: implications for human disease</article-title><source>Free Radic. Biol. Med.</source><volume>88</volume><year>2015</year><fpage>362</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.06.012</pub-id><pub-id pub-id-type="pmid">26117318</pub-id>
</element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name><surname>Porokhovnik</surname><given-names>L.N.</given-names></name><name><surname>Pisarev</surname><given-names>V.M.</given-names></name><name><surname>Chumachenko</surname><given-names>A.G.</given-names></name><name><surname>Chudakova</surname><given-names>J.M.</given-names></name><name><surname>Ershova</surname><given-names>E.S.</given-names></name><name><surname>Veiko</surname><given-names>N.N.</given-names></name><name><surname>Gorbachevskaya</surname><given-names>N.L.</given-names></name><name><surname>Mamokhina</surname><given-names>U.A.</given-names></name><name><surname>Sorokin</surname><given-names>A.B.</given-names></name><name><surname>Basova</surname><given-names>A.Y.</given-names></name><name><surname>Lapshin</surname><given-names>M.S.</given-names></name><name><surname>L Izhevskaya</surname><given-names>V.</given-names></name><name><surname>Kostyuk</surname><given-names>S.V.</given-names></name></person-group><article-title>Association of NEF2L2 Rs35652124 polymorphism with Nrf2 induction and genotoxic stress biomarkers in autism</article-title><source>Genes (Basel)</source><volume>14</volume><year>2023</year><fpage>718</fpage><pub-id pub-id-type="doi">10.3390/genes14030718</pub-id><pub-id pub-id-type="pmid">36980990</pub-id>
</element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name><surname>Napoli</surname><given-names>E.</given-names></name><name><surname>Wong</surname><given-names>S.</given-names></name><name><surname>Hertz-Picciotto</surname><given-names>I.</given-names></name><name><surname>Giulivi</surname><given-names>C.</given-names></name></person-group><article-title>Deficits in bioenergetics and impaired immune response in granulocytes from children with autism</article-title><source>Pediatrics</source><volume>133</volume><year>2014</year><fpage>e1405</fpage><lpage>e1410</lpage><pub-id pub-id-type="doi">10.1542/peds.2013-1545</pub-id><pub-id pub-id-type="pmid">24753527</pub-id>
</element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name><surname>Che&#x00142;chowska</surname><given-names>M.</given-names></name><name><surname>Gajewska</surname><given-names>J.</given-names></name><name><surname>Szczepanik</surname><given-names>E.</given-names></name><name><surname>Mazur</surname><given-names>J.</given-names></name><name><surname>Cychol</surname><given-names>A.</given-names></name><name><surname>Ku&#x0017a;niar-Pa&#x00142;ka</surname><given-names>A.</given-names></name><name><surname>Ambroszkiewicz</surname><given-names>J.</given-names></name></person-group><article-title>Oxidative stress indicated by nuclear transcription factor Nrf2 and glutathione status in the blood of young children with autism spectrum disorder: pilot study</article-title><source>Antioxidants (Basel)</source><volume>14</volume><year>2025</year><fpage>320</fpage><pub-id pub-id-type="doi">10.3390/antiox14030320</pub-id><pub-id pub-id-type="pmid">40227289</pub-id>
</element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name><surname>Subasi Turgut</surname><given-names>F.</given-names></name><name><surname>Karadag</surname><given-names>M.</given-names></name><name><surname>Taysi</surname><given-names>S.</given-names></name><name><surname>Hang&#x000fc;l</surname><given-names>Z.</given-names></name><name><surname>Gokcen</surname><given-names>C.</given-names></name></person-group><article-title>NRF2, KEAP1 and GSK-3 levels in autism spectrum disorder: a case control study</article-title><source>Int. J. Dev. Disabil.</source><volume>70</volume><year>2024</year><fpage>1441</fpage><lpage>1451</lpage><pub-id pub-id-type="doi">10.1080/20473869.2023.2185959</pub-id><pub-id pub-id-type="pmid">39713511</pub-id>
</element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name><surname>Caracci</surname><given-names>M.O.</given-names></name><name><surname>&#x000c1;vila</surname><given-names>M.E.</given-names></name><name><surname>De Ferrari</surname><given-names>G.V.</given-names></name></person-group><article-title>Synaptic Wnt/GSK3&#x003b2; signaling hub in autism</article-title><source>Neural Plast.</source><volume>2016</volume><year>2016</year><object-id pub-id-type="publisher-id">9603751</object-id><pub-id pub-id-type="doi">10.1155/2016/9603751</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Hao</surname><given-names>Y.</given-names></name></person-group><article-title>IL-6 enhances the activation of PI3K-AKT/mTOR-GSK-3&#x003b2; by upregulating GRPR in hippocampal neurons of autistic mice</article-title><source>J. Neuroimmune Pharmacol.</source><volume>19</volume><year>2024</year><fpage>12</fpage><pub-id pub-id-type="doi">10.1007/s11481-024-10111-3</pub-id><pub-id pub-id-type="pmid">38536552</pub-id>
</element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name><surname>Duque-Cartagena</surname><given-names>T.</given-names></name><name><surname>Dalla</surname><given-names>M.D.B.</given-names></name><name><surname>Mundstock</surname><given-names>E.</given-names></name><name><surname>Neto</surname><given-names>F.K.</given-names></name><name><surname>Espinoza</surname><given-names>S.A.R.</given-names></name><name><surname>de Moura</surname><given-names>S.K.</given-names></name><name><surname>Zanirati</surname><given-names>G.</given-names></name><name><surname>Padoin</surname><given-names>A.V.</given-names></name><name><surname>Jimenez</surname><given-names>J.G.P.</given-names></name><name><surname>Stein</surname><given-names>A.T.</given-names></name><name><surname>Ca&#x000f1;on-Monta&#x000f1;ez</surname><given-names>W.</given-names></name><name><surname>Mattiello</surname><given-names>R.</given-names></name></person-group><article-title>Environmental pollutants as risk factors for autism spectrum disorders: a systematic review and meta-analysis of cohort studies</article-title><source>BMC Public Health</source><volume>24</volume><year>2024</year><fpage>2388</fpage><pub-id pub-id-type="doi">10.1186/s12889-024-19742-w</pub-id><pub-id pub-id-type="pmid">39223561</pub-id>
</element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name><surname>Rossignol</surname><given-names>D.A.</given-names></name><name><surname>Genuis</surname><given-names>S.J.</given-names></name><name><surname>Frye</surname><given-names>R.E.</given-names></name></person-group><article-title>Environmental toxicants and autism spectrum disorders: a systematic review</article-title><source>Transl. Psychiatry</source><volume>4</volume><year>2014</year><fpage>e360</fpage><pub-id pub-id-type="doi">10.1038/tp.2014.4</pub-id><comment>e360</comment><pub-id pub-id-type="pmid">24518398</pub-id>
</element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name><surname>Nadeem</surname><given-names>A.</given-names></name><name><surname>Ahmad</surname><given-names>S.F.</given-names></name><name><surname>Al-Harbi</surname><given-names>N.O.</given-names></name><name><surname>Al-Ayadhi</surname><given-names>L.Y.</given-names></name><name><surname>Alanazi</surname><given-names>M.M.</given-names></name><name><surname>Alfardan</surname><given-names>A.S.</given-names></name><name><surname>Attia</surname><given-names>S.M.</given-names></name><name><surname>Algahtani</surname><given-names>M.</given-names></name><name><surname>Bakheet</surname><given-names>S.A.</given-names></name></person-group><article-title>Dysregulated Nrf2 signaling in response to di(2-ethylhexyl) phthalate in neutrophils of children with autism</article-title><source>Int. Immunopharmacol.</source><volume>106</volume><year>2022</year><object-id pub-id-type="publisher-id">108619</object-id><pub-id pub-id-type="doi">10.1016/j.intimp.2022.108619</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name><surname>Schrier</surname><given-names>M.S.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Trivedi</surname><given-names>M.S.</given-names></name><name><surname>Deth</surname><given-names>R.C.</given-names></name></person-group><article-title>Decreased cortical Nrf2 gene expression in autism and its relationship to thiol and cobalamin status</article-title><source>Biochimie</source><volume>192</volume><year>2022</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2021.09.006</pub-id><pub-id pub-id-type="pmid">34517051</pub-id>
</element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name><surname>Stanger</surname><given-names>O.</given-names></name><name><surname>Fowler</surname><given-names>B.</given-names></name><name><surname>Piertzik</surname><given-names>K.</given-names></name><name><surname>Huemer</surname><given-names>M.</given-names></name><name><surname>Haschke-Becher</surname><given-names>E.</given-names></name><name><surname>Semmler</surname><given-names>A.</given-names></name><name><surname>Lorenzl</surname><given-names>S.</given-names></name><name><surname>Linnebank</surname><given-names>M.</given-names></name></person-group><article-title>Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations</article-title><source>Expert Rev. Neurother.</source><volume>9</volume><year>2009</year><fpage>1393</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1586/ern.09.75</pub-id><pub-id pub-id-type="pmid">19769453</pub-id>
</element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name><surname>Fuentes-Albero</surname><given-names>M.</given-names></name><name><surname>Cauli</surname><given-names>O.</given-names></name></person-group><article-title>Homocysteine levels in autism spectrum disorder: a clinical update</article-title><source>Endocr., Metab. Immune Disord.: Drug Targets</source><volume>18</volume><year>2018</year><fpage>289</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.2174/1871530318666180213110815</pub-id><pub-id pub-id-type="pmid">29437021</pub-id>
</element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Hodgson</surname><given-names>N.W.</given-names></name><name><surname>Trivedi</surname><given-names>M.S.</given-names></name><name><surname>Abdolmaleky</surname><given-names>H.M.</given-names></name><name><surname>Fournier</surname><given-names>M.</given-names></name><name><surname>Cuenod</surname><given-names>M.</given-names></name><name><surname>Do</surname><given-names>K.Q.</given-names></name><name><surname>Deth</surname><given-names>R.C.</given-names></name></person-group><article-title>Decreased brain levels of vitamin B12 in aging, autism and schizophrenia</article-title><source>PLoS One</source><volume>11</volume><year>2016</year><object-id pub-id-type="publisher-id">e0146797</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0146797</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name><surname>Depino</surname><given-names>A.M.</given-names></name></person-group><article-title>Peripheral and central inflammation in autism spectrum disorders</article-title><source>Mol. Cell. Neurosci.</source><volume>53</volume><year>2013</year><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2012.10.003</pub-id><pub-id pub-id-type="pmid">23069728</pub-id>
</element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>S.</given-names></name><name><surname>Buttari</surname><given-names>B.</given-names></name><name><surname>Panieri</surname><given-names>E.</given-names></name><name><surname>Profumo</surname><given-names>E.</given-names></name><name><surname>Saso</surname><given-names>L.</given-names></name></person-group><article-title>An overview of Nrf2 signaling pathway and its role in inflammation</article-title><source>Molecules (Basel, Switzerland)</source><volume>25</volume><year>2020</year><pub-id pub-id-type="doi">10.3390/molecules25225474</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name><surname>Nadeem</surname><given-names>A.</given-names></name><name><surname>Ahmad</surname><given-names>S.F.</given-names></name><name><surname>Al-Ayadhi</surname><given-names>L.Y.</given-names></name><name><surname>Attia</surname><given-names>S.M.</given-names></name><name><surname>Al-Harbi</surname><given-names>N.O.</given-names></name><name><surname>Alzahrani</surname><given-names>K.S.</given-names></name><name><surname>Bakheet</surname><given-names>S.A.</given-names></name></person-group><article-title>Differential regulation of Nrf2 is linked to elevated inflammation and nitrative stress in monocytes of children with autism</article-title><source>Psychoneuroendocrinology</source><volume>113</volume><year>2020</year><object-id pub-id-type="publisher-id">104554</object-id><pub-id pub-id-type="doi">10.1016/j.psyneuen.2019.104554</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name><surname>Fourquet</surname><given-names>S.</given-names></name><name><surname>Guerois</surname><given-names>R.</given-names></name><name><surname>Biard</surname><given-names>D.</given-names></name><name><surname>Toledano</surname><given-names>M.B.</given-names></name></person-group><article-title>Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation</article-title><source>J. Biol. Chem.</source><volume>285</volume><year>2010</year><fpage>8463</fpage><lpage>8471</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.051714</pub-id><pub-id pub-id-type="pmid">20061377</pub-id>
</element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>K.W.</given-names></name><name><surname>Choi</surname><given-names>S.H.</given-names></name><name><surname>Kim</surname><given-names>S.G.</given-names></name></person-group><article-title>Peroxynitrite activates NF-E2-related factor 2/antioxidant response element through the pathway of phosphatidylinositol 3-kinase: the role of nitric oxide synthase in rat glutathione S-transferase A2 induction</article-title><source>Nitric Oxide</source><volume>7</volume><year>2002</year><fpage>244</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/s1089-8603(02)00117-9</pub-id><pub-id pub-id-type="pmid">12446173</pub-id>
</element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name><surname>Tebay</surname><given-names>L.E.</given-names></name><name><surname>Robertson</surname><given-names>H.</given-names></name><name><surname>Durant</surname><given-names>S.T.</given-names></name><name><surname>Vitale</surname><given-names>S.R.</given-names></name><name><surname>Penning</surname><given-names>T.M.</given-names></name><name><surname>Dinkova-Kostova</surname><given-names>A.T.</given-names></name><name><surname>Hayes</surname><given-names>J.D.</given-names></name></person-group><article-title>Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease</article-title><source>Free Radic. Biol. Med.</source><volume>88</volume><year>2015</year><fpage>108</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.06.021</pub-id><pub-id pub-id-type="pmid">26122708</pub-id>
</element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name><surname>Napolitano</surname><given-names>A.</given-names></name><name><surname>Schiavi</surname><given-names>S.</given-names></name><name><surname>La Rosa</surname><given-names>P.</given-names></name><name><surname>Rossi-Espagnet</surname><given-names>M.C.</given-names></name><name><surname>Petrillo</surname><given-names>S.</given-names></name><name><surname>Bottino</surname><given-names>F.</given-names></name><name><surname>Tagliente</surname><given-names>E.</given-names></name><name><surname>Longo</surname><given-names>D.</given-names></name><name><surname>Lupi</surname><given-names>E.</given-names></name><name><surname>Casula</surname><given-names>L.</given-names></name><name><surname>Valeri</surname><given-names>G.</given-names></name><name><surname>Piemonte</surname><given-names>F.</given-names></name><name><surname>Trezza</surname><given-names>V.</given-names></name><name><surname>Vicari</surname><given-names>S.</given-names></name></person-group><article-title>Sex differences in autism spectrum disorder: diagnostic, neurobiological, and behavioral features</article-title><source>Front. Psychiatr.</source><volume>13</volume><year>2022</year><pub-id pub-id-type="doi">10.3389/fpsyt.2022.889636</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name><surname>Bove</surname><given-names>M.</given-names></name><name><surname>Sikora</surname><given-names>V.</given-names></name><name><surname>Santoro</surname><given-names>M.</given-names></name><name><surname>Agosti</surname><given-names>L.P.</given-names></name><name><surname>Palmieri</surname><given-names>M.A.</given-names></name><name><surname>Dimonte</surname><given-names>S.</given-names></name><name><surname>Tucci</surname><given-names>P.</given-names></name><name><surname>Schiavone</surname><given-names>S.</given-names></name><name><surname>Morgese</surname><given-names>M.G.</given-names></name><name><surname>Trabace</surname><given-names>L.</given-names></name></person-group><article-title>Sex differences in the BTBR idiopathic mouse model of autism spectrum disorders: behavioural and redox-related hippocampal alterations</article-title><source>Neuropharmacology</source><volume>260</volume><year>2024</year><object-id pub-id-type="publisher-id">110134</object-id><pub-id pub-id-type="doi">10.1016/j.neuropharm.2024.110134</pub-id></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Si</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Xie</surname><given-names>W.</given-names></name><name><surname>Yue</surname><given-names>Z.</given-names></name><name><surname>Yong</surname><given-names>J.</given-names></name><name><surname>Dai</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Shank3 ameliorates neuronal injury after cerebral ischemia/reperfusion via inhibiting oxidative stress and inflammation</article-title><source>Redox Biol.</source><volume>69</volume><year>2024</year><object-id pub-id-type="publisher-id">102983</object-id><pub-id pub-id-type="doi">10.1016/j.redox.2023.102983</pub-id></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name><surname>Varma</surname><given-names>M.</given-names></name><name><surname>Bhandari</surname><given-names>R.</given-names></name><name><surname>Sarkar</surname><given-names>A.</given-names></name><name><surname>Jain</surname><given-names>M.</given-names></name><name><surname>Paliwal</surname><given-names>J.K.</given-names></name><name><surname>Medhi</surname><given-names>B.</given-names></name><name><surname>Kuhad</surname><given-names>A.</given-names></name></person-group><article-title>Exploring astrocytes involvement and glutamate induced neuroinflammation in chlorpyrifos-induced paradigm of autism spectrum disorders (ASD)</article-title><source>Neurochem. Res.</source><volume>49</volume><year>2024</year><fpage>2573</fpage><lpage>2599</lpage><pub-id pub-id-type="doi">10.1007/s11064-024-04191-z</pub-id><pub-id pub-id-type="pmid">38896196</pub-id>
</element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name><surname>Furnari</surname><given-names>M.A.</given-names></name><name><surname>Saw</surname><given-names>C.L.-L.</given-names></name><name><surname>Kong</surname><given-names>A.-N.</given-names></name><name><surname>Wagner</surname><given-names>G.C.</given-names></name></person-group><article-title>Altered behavioral development in Nrf2 knockout mice following early postnatal exposure to valproic acid</article-title><source>Brain Res. Bull.</source><volume>109</volume><year>2014</year><fpage>132</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2014.10.006</pub-id><pub-id pub-id-type="pmid">25454122</pub-id>
</element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name><surname>Ku&#x0017a;niar-Pa&#x00142;ka</surname><given-names>A.</given-names></name></person-group><article-title>The role of oxidative stress in autism spectrum disorder pathophysiology, diagnosis and treatment</article-title><source>Biomedicines</source><volume>13</volume><year>2025</year><fpage>388</fpage><pub-id pub-id-type="doi">10.3390/biomedicines13020388</pub-id><pub-id pub-id-type="pmid">40002801</pub-id>
</element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name><surname>Calabrese</surname><given-names>V.</given-names></name><name><surname>Cornelius</surname><given-names>C.</given-names></name><name><surname>Stella</surname><given-names>A.M.G.</given-names></name><name><surname>Calabrese</surname><given-names>E.J.</given-names></name></person-group><article-title>Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: role of hormesis and vitagenes</article-title><source>Neurochem. Res.</source><volume>35</volume><year>2010</year><fpage>1880</fpage><lpage>1915</lpage><pub-id pub-id-type="doi">10.1007/s11064-010-0307-z</pub-id><pub-id pub-id-type="pmid">21080068</pub-id>
</element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name><surname>Calabrese</surname><given-names>V.</given-names></name><name><surname>Colombrita</surname><given-names>C.</given-names></name><name><surname>Guagliano</surname><given-names>E.</given-names></name><name><surname>Sapienza</surname><given-names>M.</given-names></name><name><surname>Ravagna</surname><given-names>A.</given-names></name><name><surname>Cardile</surname><given-names>V.</given-names></name><name><surname>Scapagnini</surname><given-names>G.</given-names></name><name><surname>Santoro</surname><given-names>A.M.</given-names></name><name><surname>Mangiameli</surname><given-names>A.</given-names></name><name><surname>Butterfield</surname><given-names>D.A.</given-names></name><name><surname>Stella</surname><given-names>A.M.G.</given-names></name><name><surname>Rizzarelli</surname><given-names>E.</given-names></name></person-group><article-title>Protective effect of carnosine during nitrosative stress in astroglial cell cultures</article-title><source>Neurochem. Res.</source><volume>30</volume><year>2005</year><fpage>797</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1007/s11064-005-6874-8</pub-id><pub-id pub-id-type="pmid">16187215</pub-id>
</element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D.D.</given-names></name></person-group><article-title>Thirty years of NRF2: advances and therapeutic challenges</article-title><source>Nat. Rev. Drug Discov.</source><year>2025</year><pub-id pub-id-type="doi">10.1038/s41573-025-01145-0</pub-id></element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>S.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name></person-group><article-title>Antioxidant interventions in autism spectrum disorders: a meta-analysis</article-title><source>Prog. Neuro Psychopharmacol. Biol. Psychiatr.</source><volume>113</volume><year>2022</year><object-id pub-id-type="publisher-id">110476</object-id><pub-id pub-id-type="doi">10.1016/j.pnpbp.2021.110476</pub-id></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name><surname>Savino</surname><given-names>R.</given-names></name><name><surname>Medoro</surname><given-names>A.</given-names></name><name><surname>Ali</surname><given-names>S.</given-names></name><name><surname>Scapagnini</surname><given-names>G.</given-names></name><name><surname>Maes</surname><given-names>M.</given-names></name><name><surname>Davinelli</surname><given-names>S.</given-names></name></person-group><article-title>The emerging role of flavonoids in autism spectrum disorder: a systematic review</article-title><source>J. Clin. Med.</source><volume>12</volume><year>2023</year><fpage>3520</fpage><pub-id pub-id-type="doi">10.3390/jcm12103520</pub-id><pub-id pub-id-type="pmid">37240625</pub-id>
</element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="journal" id="sref148"><person-group person-group-type="author"><name><surname>Sestan</surname><given-names>N.</given-names></name><name><surname>State</surname><given-names>M.W.</given-names></name></person-group><article-title>Lost in translation: traversing the complex path from genomics to therapeutics in autism spectrum disorder</article-title><source>Neuron</source><volume>100</volume><year>2018</year><fpage>406</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.10.015</pub-id><pub-id pub-id-type="pmid">30359605</pub-id>
</element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>J.L.</given-names></name><name><surname>Thurm</surname><given-names>A.</given-names></name><name><surname>Ethridge</surname><given-names>S.B.</given-names></name><name><surname>Soller</surname><given-names>M.M.</given-names></name><name><surname>Petkova</surname><given-names>S.P.</given-names></name><name><surname>Abel</surname><given-names>T.</given-names></name><name><surname>Bauman</surname><given-names>M.D.</given-names></name><name><surname>Brodkin</surname><given-names>E.S.</given-names></name><name><surname>Harony-Nicolas</surname><given-names>H.</given-names></name><name><surname>W&#x000f6;hr</surname><given-names>M.</given-names></name><name><surname>Halladay</surname><given-names>A.</given-names></name></person-group><article-title>Reconsidering animal models used to study autism spectrum disorder: current state and optimizing future</article-title><source>Gene Brain Behav.</source><volume>21</volume><year>2022</year><pub-id pub-id-type="doi">10.1111/GBB.12803</pub-id></element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name><surname>Bernuzzi</surname><given-names>F.</given-names></name><name><surname>Maertens</surname><given-names>A.</given-names></name><name><surname>Saha</surname><given-names>S.</given-names></name><name><surname>Troncoso-Rey</surname><given-names>P.</given-names></name><name><surname>Ludwig</surname><given-names>T.</given-names></name><name><surname>Hiller</surname><given-names>K.</given-names></name><name><surname>Mithen</surname><given-names>R.F.</given-names></name><name><surname>Korcsmaros</surname><given-names>T.</given-names></name><name><surname>Traka</surname><given-names>M.H.</given-names></name></person-group><article-title>Sulforaphane rewires central metabolism to support antioxidant response and achieve glucose homeostasis</article-title><source>Redox Biol.</source><volume>67</volume><year>2023</year><object-id pub-id-type="publisher-id">102878</object-id><pub-id pub-id-type="doi">10.1016/j.redox.2023.102878</pub-id></element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name><surname>Dinkova-Kostova</surname><given-names>A.T.</given-names></name><name><surname>Fahey</surname><given-names>J.W.</given-names></name><name><surname>Kostov</surname><given-names>R.V.</given-names></name><name><surname>Kensler</surname><given-names>T.W.</given-names></name></person-group><article-title>KEAP1 and done? Targeting the NRF2 pathway with sulforaphane</article-title><source>Trends Food Sci. Technol.</source><volume>69</volume><year>2017</year><fpage>257</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.tifs.2017.02.002</pub-id><pub-id pub-id-type="pmid">29242678</pub-id>
</element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Eggler</surname><given-names>A.L.</given-names></name><name><surname>Mesecar</surname><given-names>A.D.</given-names></name><name><surname>van Breemen</surname><given-names>R.B.</given-names></name></person-group><article-title>Modification of Keap1 cysteine residues by sulforaphane</article-title><source>Chem. Res. Toxicol.</source><volume>24</volume><year>2011</year><fpage>515</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1021/tx100389r</pub-id><pub-id pub-id-type="pmid">21391649</pub-id>
</element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Connors</surname><given-names>S.L.</given-names></name><name><surname>Macklin</surname><given-names>E.A.</given-names></name><name><surname>Smith</surname><given-names>K.D.</given-names></name><name><surname>Fahey</surname><given-names>J.W.</given-names></name><name><surname>Talalay</surname><given-names>P.</given-names></name><name><surname>Zimmerman</surname><given-names>A.W.</given-names></name></person-group><article-title>Sulforaphane treatment of autism spectrum disorder (ASD)</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>111</volume><year>2014</year><fpage>15550</fpage><lpage>15555</lpage><pub-id pub-id-type="doi">10.1073/pnas.1416940111</pub-id><pub-id pub-id-type="pmid">25313065</pub-id>
</element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>R.</given-names></name><name><surname>Diggins</surname><given-names>E.L.</given-names></name><name><surname>Connors</surname><given-names>S.L.</given-names></name><name><surname>Zimmerman</surname><given-names>A.W.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Talalay</surname><given-names>P.</given-names></name><name><surname>Fahey</surname><given-names>J.W.</given-names></name></person-group><article-title>Sulforaphane from broccoli reduces symptoms of autism: a follow-up case series from a randomized double-blind study</article-title><source>Glob. Adv. Health Med.</source><volume>6</volume><year>2017</year><object-id pub-id-type="publisher-id">2164957X17735826</object-id><pub-id pub-id-type="doi">10.1177/2164957X17735826</pub-id></element-citation></ref><ref id="bib155"><label>155</label><element-citation publication-type="journal" id="sref155"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>A.W.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Connors</surname><given-names>S.L.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Panjwani</surname><given-names>A.A.</given-names></name><name><surname>Lee</surname><given-names>L.-C.</given-names></name><name><surname>Diggins</surname><given-names>E.</given-names></name><name><surname>Foley</surname><given-names>A.</given-names></name><name><surname>Melnyk</surname><given-names>S.</given-names></name><name><surname>Singh</surname><given-names>I.N.</given-names></name><name><surname>James</surname><given-names>S.J.</given-names></name><name><surname>Frye</surname><given-names>R.E.</given-names></name><name><surname>Fahey</surname><given-names>J.W.</given-names></name></person-group><article-title>Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder</article-title><source>Mol. Autism</source><volume>12</volume><year>2021</year><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/s13229-021-00447-5</pub-id><pub-id pub-id-type="pmid">34034808</pub-id>
</element-citation></ref><ref id="bib156"><label>156</label><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name><surname>Momtazmanesh</surname><given-names>S.</given-names></name><name><surname>Amirimoghaddam-Yazdi</surname><given-names>Z.</given-names></name><name><surname>Moghaddam</surname><given-names>H.S.</given-names></name><name><surname>Mohammadi</surname><given-names>M.R.</given-names></name><name><surname>Akhondzadeh</surname><given-names>S.</given-names></name></person-group><article-title>Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial</article-title><source>Psychiatr. Clin. Neurosci.</source><volume>74</volume><year>2020</year><fpage>398</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1111/pcn.13016</pub-id></element-citation></ref><ref id="bib157"><label>157</label><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name><surname>Bent</surname><given-names>S.</given-names></name><name><surname>Lawton</surname><given-names>B.</given-names></name><name><surname>Warren</surname><given-names>T.</given-names></name><name><surname>Widjaja</surname><given-names>F.</given-names></name><name><surname>Dang</surname><given-names>K.</given-names></name><name><surname>Fahey</surname><given-names>J.W.</given-names></name><name><surname>Cornblatt</surname><given-names>B.</given-names></name><name><surname>Kinchen</surname><given-names>J.M.</given-names></name><name><surname>Delucchi</surname><given-names>K.</given-names></name><name><surname>Hendren</surname><given-names>R.L.</given-names></name></person-group><article-title>Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli</article-title><source>Mol. Autism</source><volume>9</volume><year>2018</year><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/s13229-018-0218-4</pub-id><pub-id pub-id-type="pmid">29854372</pub-id>
</element-citation></ref><ref id="bib158"><label>158</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>R.C.</given-names></name><name><surname>Tobe</surname><given-names>R.H.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Arriaza</surname><given-names>J.</given-names></name><name><surname>Fahey</surname><given-names>J.W.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Zeng</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>D.</given-names></name><name><surname>Cornblatt</surname><given-names>B.</given-names></name><name><surname>Davis</surname><given-names>J.M.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>R.</given-names></name><name><surname>Jin</surname><given-names>H.</given-names></name></person-group><article-title>Efficacy of sulforaphane in treatment of children with autism spectrum disorder: a randomized double-blind placebo-controlled multi-center trial</article-title><source>J. Autism Dev. Disord.</source><volume>54</volume><year>2024</year><fpage>628</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1007/s10803-022-05784-9</pub-id><pub-id pub-id-type="pmid">36427174</pub-id>
</element-citation></ref><ref id="bib159"><label>159</label><element-citation publication-type="journal" id="sref159"><person-group person-group-type="author"><name><surname>Magner</surname><given-names>M.</given-names></name><name><surname>Thorov&#x000e1;</surname><given-names>K.</given-names></name><name><surname>&#x0017d;upov&#x000e1;</surname><given-names>V.</given-names></name><name><surname>Hou&#x00161;ka</surname><given-names>M.</given-names></name><name><surname>&#x00160;vandov&#x000e1;</surname><given-names>I.</given-names></name><name><surname>Novotn&#x000e1;</surname><given-names>P.</given-names></name><name><surname>T&#x00159;&#x000ed;ska</surname><given-names>J.</given-names></name><name><surname>Vrchotov&#x000e1;</surname><given-names>N.</given-names></name><name><surname>Soural</surname><given-names>I.</given-names></name><name><surname>J&#x000ed;lek</surname><given-names>L.</given-names></name></person-group><article-title>Sulforaphane treatment in children with autism: a prospective randomized double-blind study</article-title><source>Nutrients</source><volume>15</volume><year>2023</year><fpage>718</fpage><pub-id pub-id-type="doi">10.3390/nu15030718</pub-id><pub-id pub-id-type="pmid">36771424</pub-id>
</element-citation></ref><ref id="bib160"><label>160</label><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name><surname>Kalyanaraman</surname><given-names>B.</given-names></name><name><surname>Nac</surname><given-names>N.A.C.</given-names></name></person-group><article-title>Knockin&#x02019; on Heaven's door: interpreting the mechanism of action of N-acetylcysteine in tumor and immune cells</article-title><source>Redox Biol.</source><volume>57</volume><year>2022</year><object-id pub-id-type="publisher-id">102497</object-id><pub-id pub-id-type="doi">10.1016/j.redox.2022.102497</pub-id></element-citation></ref><ref id="bib161"><label>161</label><element-citation publication-type="journal" id="sref161"><person-group person-group-type="author"><name><surname>Khanna</surname><given-names>A.K.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Mehra</surname><given-names>M.R.</given-names></name></person-group><article-title>Antioxidant N-acetyl cysteine reverses cigarette smoke-induced myocardial infarction by inhibiting inflammation and oxidative stress in a rat model</article-title><source>Lab. Invest.</source><volume>92</volume><year>2012</year><fpage>224</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1038/labinvest.2011.146</pub-id><pub-id pub-id-type="pmid">21968809</pub-id>
</element-citation></ref><ref id="bib162"><label>162</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Fang</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Ding</surname><given-names>K.</given-names></name></person-group><article-title>N-acetylcysteine amide provides neuroprotection via Nrf2-ARE pathway in a mouse model of traumatic brain injury</article-title><source>DDDT</source><volume>12</volume><year>2018</year><fpage>4117</fpage><lpage>4127</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S179227</pub-id><pub-id pub-id-type="pmid">30584276</pub-id>
</element-citation></ref><ref id="bib163"><label>163</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name><surname>Dean</surname><given-names>O.M.</given-names></name><name><surname>Gray</surname><given-names>K.M.</given-names></name><name><surname>Villagonzalo</surname><given-names>K.-A.</given-names></name><name><surname>Dodd</surname><given-names>S.</given-names></name><name><surname>Mohebbi</surname><given-names>M.</given-names></name><name><surname>Vick</surname><given-names>T.</given-names></name><name><surname>Tonge</surname><given-names>B.J.</given-names></name><name><surname>Berk</surname><given-names>M.</given-names></name></person-group><article-title>A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder</article-title><source>Aust. N. Z. J. Psychiatr.</source><volume>51</volume><year>2017</year><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1177/0004867416652735</pub-id></element-citation></ref><ref id="bib164"><label>164</label><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name><surname>Wink</surname><given-names>L.K.</given-names></name><name><surname>Adams</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Klaunig</surname><given-names>J.E.</given-names></name><name><surname>Plawecki</surname><given-names>M.H.</given-names></name><name><surname>Posey</surname><given-names>D.J.</given-names></name><name><surname>McDougle</surname><given-names>C.J.</given-names></name><name><surname>Erickson</surname><given-names>C.A.</given-names></name></person-group><article-title>A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder</article-title><source>Mol. Autism</source><volume>7</volume><year>2016</year><fpage>26</fpage><pub-id pub-id-type="doi">10.1186/s13229-016-0088-6</pub-id><pub-id pub-id-type="pmid">27103982</pub-id>
</element-citation></ref><ref id="bib165"><label>165</label><element-citation publication-type="journal" id="sref165"><person-group person-group-type="author"><name><surname>Hardan</surname><given-names>A.Y.</given-names></name><name><surname>Fung</surname><given-names>L.K.</given-names></name><name><surname>Libove</surname><given-names>R.A.</given-names></name><name><surname>Obukhanych</surname><given-names>T.V.</given-names></name><name><surname>Nair</surname><given-names>S.</given-names></name><name><surname>Herzenberg</surname><given-names>L.A.</given-names></name><name><surname>Frazier</surname><given-names>T.W.</given-names></name><name><surname>Tirouvanziam</surname><given-names>R.</given-names></name></person-group><article-title>A randomized controlled pilot trial of oral N-acetylcysteine in children with autism</article-title><source>Biol. Psychiatry</source><volume>71</volume><year>2012</year><fpage>956</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2012.01.014</pub-id><pub-id pub-id-type="pmid">22342106</pub-id>
</element-citation></ref><ref id="bib166"><label>166</label><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>P.G.</given-names></name><name><surname>Sears</surname><given-names>L.</given-names></name><name><surname>Watson</surname><given-names>W.H.</given-names></name><name><surname>Gunaratnam</surname><given-names>B.</given-names></name><name><surname>Feygin</surname><given-names>Y.</given-names></name><name><surname>Wright</surname><given-names>S.P.</given-names></name><name><surname>Sullivan</surname><given-names>J.E.</given-names></name></person-group><article-title>Glutathione, vitamin C, and cysteine use in autistic children with disruptive behavior: a double-blind, placebo-controlled crossover pilot study</article-title><source>J. Dev. Behav. Pediatr.</source><volume>46</volume><year>2025</year><fpage>e17</fpage><lpage>e24</lpage><pub-id pub-id-type="doi">10.1097/DBP.0000000000001334</pub-id><pub-id pub-id-type="pmid">39960783</pub-id>
</element-citation></ref><ref id="bib167"><label>167</label><element-citation publication-type="journal" id="sref167"><person-group person-group-type="author"><name><surname>Ghanizadeh</surname><given-names>A.</given-names></name><name><surname>Moghimi-Sarani</surname><given-names>E.</given-names></name></person-group><article-title>A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders</article-title><source>BMC Psychiatry</source><volume>13</volume><year>2013</year><fpage>196</fpage><pub-id pub-id-type="doi">10.1186/1471-244X-13-196</pub-id><pub-id pub-id-type="pmid">23886027</pub-id>
</element-citation></ref><ref id="bib168"><label>168</label><element-citation publication-type="journal" id="sref168"><person-group person-group-type="author"><name><surname>Nikoo</surname><given-names>M.</given-names></name><name><surname>Radnia</surname><given-names>H.</given-names></name><name><surname>Farokhnia</surname><given-names>M.</given-names></name><name><surname>Mohammadi</surname><given-names>M.-R.</given-names></name><name><surname>Akhondzadeh</surname><given-names>S.</given-names></name></person-group><article-title>N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety</article-title><source>Clin. Neuropharmacol.</source><volume>38</volume><year>2015</year><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1097/WNF.0000000000000063</pub-id><pub-id pub-id-type="pmid">25580916</pub-id>
</element-citation></ref></ref-list><sec sec-type="data-availability" id="da0010"><title>Data availability</title><p id="p0035">No data was used for the research described in the article.</p></sec></back></article>